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1 Abbreviations and Symbols 
~ Approximately 
°C Degree Celsius 
Δ Difference 
∞ Infinity 
ACM Adult rat cardiomyocyte 
AngII Angiotensin II 
ANOVA Analysis of variance 
ATP Adenosine triphosphate 
Bambi BMP and activin membrane-bound inhibitor homolog 
c Molar concentration 
CCL2 C-C motif chemokine 2 
cDNA Complementary deoxyribonucleic acid 
DAMP Damage associated molecular pattern 
DMEM Dulbecco's Modified Eagle's Medium  
ECM Extracellular matrix 
ERK1/2 Extracellular signal-regulated kinases 1 and 2 
FCS Fetal calf serum 
FDR False discovery rate 
g Gram; also acceleration of gravity on Earth 
GSEA Gene set enrichment analysis 
h Hour 
H/R Hypoxia/reoxygenation 
HMGB1 High mobility group box 1 
i.p. Intraperitoneal 
iBAQ Intensity based absolute quantification 
IL Interleukin 
I.U. International unit 
kDa Kilodalton 
L Liter 
LC-MS/MS Liquid chromatography-tandem mass spectrometry  
LDH Lactate dehydrogenase 
LPS Lipopolysaccharide 
M Molar (mol/L); also molar mass (g/mol) 
m Meter 
MI Myocardial infarction 
min Minute 
MMP Matrix metalloproteinase 
mol Mole 
mRNA Messenger RNA 
MyD88 Myeloid differentiation primary response protein 88 
n Number of biological replicates 
NFκB 
Nuclear factor kappa-light chain enhancer of activated 
B cells 
Ø Diameter 
OD Optical density 
P Passage 
P/S Penicillin-streptomycin 
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PAMP Pathogen associated molecular pattern 
PBS Dulbecco's phosphate buffered saline  
PCA Principal component analysis 
pH 
Negative decimal logarithm of the hydrogen ion 
concentration 
PRR Pattern recognition receptor 
qPCR Quantitative polymerase chain reaction 
RAGE Receptor for advanced glycation end products 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
Scr Scramble control 
SEM Standard error of the mean 
siRNA Small interfering RNA 
TGFβ Transforming growth factor beta 
TIMP Tissue inhibitor of metalloproteinases 
TLR Toll-like receptor 
TNFα Tumor necrosis factor alpha 
TRIF 
Toll/interleukin-1 receptor domain containing adaptor 
protein inducing interferon beta 
αSMA Alpha smooth muscle actin 
 
Prefixes 
c centi-10-2 
m milli-10-3 
µ micro-10-6 
n nano-10-9 
p pico-10-12 
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2 Summary 
Despite advancement of therapeutic strategies, myocardial infarction (MI) and subsequent 
heart failure are still the leading causes of death and disability worldwide. Development of 
new therapeutic approaches is hampered by insufficient knowledge of the cellular and 
molecular mechanisms underlying myocardial repair. S100A1 is a Ca2+ governing protein 
in cardiomyocytes. When released upon MI, S100A1 targets neighboring cardiac 
fibroblasts and is thereby essential for preserving the left ventricular function. The aim of 
this study was to systematically assess the phenotype of cardiac fibroblasts in response 
to extracellular S100A1 by comprehensive gene expression and protein profile analysis. 
In order to mimic the ischemic myocardium, adult rat cardiac fibroblasts were exposed to 
extracellular S100A1. Using RNA microarray technology, a time-resolved transcriptome 
analysis revealed a rapid activation of gene sets involved in chemoattractance alongside 
downregulation of pro-fibrotic genes. Since the dominant functional changes comprised 
secreted proteins, a complete secretome analysis of the cardiac fibroblast supernatant 
was performed by mass spectrometry. On protein level, enrichment analysis highlighted 
chemotaxis, chemokine receptor binding, and chemokine activity as the predominantly 
increased categories upon exposure to S100A1. Chemoattractants formed the most 
abundantly secreted group of proteins in S100A1-treated cardiac fibroblasts, with CCL2 
showing the highest quantity. A prominent early-onset increase of CCL2 expression and 
secretion in response to S100A1 was confirmed by qPCR and ELISA. S100A1-induced 
CCL2 expression increase was abolished by chemical inhibition and siRNA knockdown of 
TLR4.  
This study demonstrates for the first time a rapid transformation of cardiac fibroblasts into 
a chemoattractant phenotype upon exposure to S100A1 from damaged cardiomyocytes. 
These results suggest a novel role for cardiac fibroblasts as the initial link between 
ischemic injury and the influx of inflammatory cells in the process of myocardial repair.  
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3 Zusammenfassung 
Trotz moderner Therapiemöglichkeiten stellen Myokardinfarkt und nachfolgende 
Herzinsuffizienz weltweit noch immer die häufigsten Ursachen von Tod und Invalidität dar. 
Die Entwicklung neuer Therapieansätze verlangt eine Entschlüsselung der zellulären und 
molekularen Mechanismen, die der Infarktheilung zugrunde liegen. S100A1 ist ein 
zentraler Regulator des Ca2+ Stoffwechsels in Kardiomyozyten. Bei Myokardinfarkt 
freigesetztes S100A1 verändert benachbarte kardiale Fibroblasten und ist dadurch 
wesentlich am Erhalt der linksventrikulären Pumpfunktion beteiligt. Ziel der vorliegenden 
Studie war die systematische Charakterisierung des S100A1-induzierten Phänotyps 
kardialer Fibroblasten mittels vollständiger Analyse von Genexpressions-  und 
Proteinprofil.  
Um die Situation im ischämischen Myokard zu imitieren, wurden aus adulten Rattenherzen 
isolierte kardiale Fibroblasten mit extrazellulärem S100A1 stimuliert. Eine serielle 
Transkriptom-Analyse mittels RNA Microarray zeigte eine schnelle Aktivierung von Genen, 
die mit der Freisetzung von Chemokinen in Verbindung stehen. Gleichzeitig war eine 
verminderte Expression von pro-fibrotischen Faktoren zu beobachten. Da die 
beobachteten Veränderungen im Genexpressionsmuster  überwiegend sezernierte 
Proteine betrafen, wurde eine Sekretom-Analyse des Überstands kardialer Fibroblasten 
mittels Massenspektrometrie durchgeführt. Auf Proteinebene wurden mittels Enrichment 
Analysis  "chemotaxis", "chemokine receptor binding" und "chemokine activity" als die 
bestimmenden Merkmale von S100A1-stimulierten kardialen Fibroblasten charakterisiert. 
Unter den sezernierten Proteinen stellten Chemokine hierbei die quantitativ größte Gruppe 
dar, wobei CCL2 die höchste Abundanz aufwies. Eine frühe und deutliche Überexpression 
und Sekretion von CCL2 als Reaktion auf S100A1 wurde durch qPCR und ELISA bestätigt. 
Die S100A1-induzierte CCL2 Produktion kardialer Fibroblasten konnte durch chemische 
Inhibition und siRNA Knockdown von TLR4 gehemmt werden.   
Diese Studie zeigt erstmals eine rasche Transformation kardialer Fibroblasten in einen 
chemotaktischen Phänotyp nach Stimulation durch S100A1 aus geschädigten 
Kardiomyozyten. Diese Ergebnisse deuten darauf hin, dass kardialen Fibroblasten beim 
Myokardinfarkt eine neue Funktion als initiale Verknüpfung zwischen ischämischer 
Schädigung und Immunzellinfiltration zukommen könnte. 
Introduction 
8 
 
4 Introduction 
4.1 Myocardial Infarction 
4.1.1 Definition and Epidemiology 
Myocardial infarction is defined as myocardial necrosis due to acute myocardial ischemia 
[1]. There are two major types of myocardial infarction representing different causal 
mechanisms. The main cause of necrotic injury in the heart (type I myocardial infarction) 
is the blockage of a coronary blood vessel by a thrombus due to the rupture of an 
atherosclerotic plaque. Alternatively, type II myocardial infarction occurs in response to an 
acute imbalance of myocardial demand and supply for oxygen, which can be caused by 
endothelial dysfunction, tachy- or bradycardia, severe hypo- or hypertension, vasospasm, 
or respiratory failure [1].  
Clinically, myocardial infarction is characterized by typical ischemic chest pain symptoms, 
electrocardiographic abnormalities, imaging technique findings, such as segmental 
ventricular akinesia in echocardiography, and by the detection of raise and/or fall of heart 
necrosis biomarkers in blood plasma, particularly cardiac troponin I or T [1–4]. The results 
of clinical and laboratory findings have to be interpreted together, thereby ensuring 
accurate differentiation between acute ischemic myocardial necrosis and myocardial 
damage due to other conditions, such as sepsis, heart failure or illicit drug use, which 
require a different therapeutic strategy [5,6].  
According to the World Health Organization, coronary heart disease and acute myocardial 
infarction are the leading causes of death and disability worldwide [7]. The major 
complication after myocardial infarction is chronic heart failure affecting 16% of men and 
22% of women within 5 years after myocardial infarction [8]. Heart failure has a negative 
prognosis for the patients with 50% mortality within 5 years and limited therapeutic options 
[9]. Factors, which favor the development of heart failure after MI, include larger size of 
initial infarction and improper healing thereafter [10]. Since the major cause of myocardial 
infarction is thrombotic occlusion of coronary arteries [11], the central therapeutic strategy 
is the timely recanalization of the culprit artery [2,3]. Since the extensive introduction of 
coronary care units and reperfusion therapies, the short term in-hospital mortality of MI 
patients has decreased from 30% in the mid of 20 century to 6% in 2006 [12,13]. Moreover, 
the success of reperfusion therapy has been attributed to 28% reduction in the incidence 
of subsequent heart failure [14] by limiting the extent of cardiomyocyte death and thus the 
size of myocardial infarction [15]. 
  Introduction 
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4.1.2 Cardiac Repair after Infarction 
Myocardial infarction is followed by a fine-tuned healing cascade which is triggered by 
ischemic cardiomyocyte death (Figure 1) [10]. Since adult cardiomyocytes possess very 
limited regenerative capacity, the necrotic area is replaced with a durable scar in order to 
ensure cardiac function [16–18].  
 
Figure 1: Healing cascade after myocardial infarction. 
(1) Coronary blood vessel obstruction is the initial phase of myocardial infarction (not the case in type 
II - mentioned earlier in the text). (2) Subsequent cardiomyocyte death triggers inflammatory cell 
influx, which is facilitated by the degradation of extracellular matrix (ECM). Neutrophils and 
macrophages collectively clear the cellular debris. (3) Myofibroblasts synthesize a collagen-based 
matrix and angiogenesis ensures the restoration of the blood flow within the newly formed scar. (4) 
A mature scar with crosslinked matrix and low amount of persistent myofibroblasts is formed.  
Early studies of temporal coronary artery occlusion, which were performed in dogs, 
revealed that 40 min of ischemia result in a macroscopically visible subendocardial 
necrosis [19]. During the initial phase after myocardial infarction cellular debris is removed 
by inflammatory cells. They also trigger the transition to the scar formation phase, during 
which myofibroblasts fill the necrotic area with a collagen-based matrix and angiogenesis 
ensures the vascularization of the newly formed scar. In the final phase, the provisional 
scar is transformed into a tightly crosslinked type I collagen-based scar (Figure 1).   
Introduction 
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4.1.2.1 Inflammation 
Cardiomyocyte injury triggers a rapid infiltration of inflammatory cells [20], which is 
facilitated by extracellular matrix degradation [21] and increased vascular permeability 
[22]. The majority of infiltrating inflammatory cell types are neutrophils and inflammatory 
and reparative monocytes that further differentiate into macrophages [23].  Inflammatory 
monocytes become M1 macrophages and, in later stages, also M2 macrophages, whereas 
reparative monocytes are considered to give rise only to M2 macrophages [24–26]. In 
mice, inflammatory cells are reported to infiltrate the infarction area within the first minutes 
after the occlusion of a coronary blood vessel. Although the first infiltrating population is 
patrolling monocytes from the vasculature [27], the following neutrophil influx forms the 
dominant cell population within the infarct in the first 24 hours [28]. Thereafter, 
inflammatory and reparative monocytes numbers peak on day 3 and 5, respectively [24].  
The sequential influx, differentiation and activity of inflammatory cells lead to clearance of 
the infarction site from cellular debris and activation of scar formation. Neutrophils produce 
a vast amount of extracellular matrix degrading proteins and reactive oxygen species that 
participate in pro-angiogenic and pro-fibrotic processes [29–31]. Neutrophils also secrete 
α-defensin that acts as a monocyte chemoattractant [32] and lipocalin that, in turn, 
promotes macrophage polarization into an M2c phenotype, which has the highest 
efferocytotic (cellular debris clearance) activity [33,34]. The subsequently differentiated M1 
macrophages participate in cellular debris efferocytosis [28] and engulf apoptotic 
neutrophils [35], thus contributing to the restriction of the acute inflammatory phase [36]. 
The engulfment of apoptotic neutrophils triggers macrophage polarization towards an M2 
phenotype [37], which is known to resolve inflammation and to initiate the scar formation 
phase by promoting angiogenesis and myofibroblast accumulation [25,38]. 
Early attempts to improve the outcome of myocardial infarction by broadly suppressing the 
inflammatory response with glucocorticoids or nonsteroidal anti-inflammatory drugs have 
provided no benefits. Although the initial experiments in dogs showed that glucocorticoids 
reduce the myocardial necrosis following infarction [39], subsequent experiments indicated 
dose-dependent scar thinning [40], thereby increasing the risk of ventricular aneurysm 
formation or rupture. The initial trials of glucocorticoids in patients with myocardial 
infarction indicated conflicting outcomes [41], but larger randomized clinical trials showed 
no survival benefits [42]. Similarly, nonsteroidal anti-inflammatory drugs initially were 
shown to reduce the infarcted area, presumably, by reducing the rate of necrosis. In dogs, 
treatment with ibuprofen reduced the size of infarct without affecting blood flow or oxygen 
demand [43]. However, further experiments showed that ibuprofen administration after 
  Introduction 
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myocardial infarction is also associated with scar thinning [44]. In humans, indomethacin 
or ibuprofen administration resulted in infarct scar thinning [45] and was suggested to be 
associated with ventricular rupture after myocardial infarction [46]. Since broad 
suppression of inflammatory response has failed to be beneficial, the ongoing search for 
new therapeutic approaches is focusing on targeted immunomodulatory strategies in order 
to improve infarct healing.      
4.1.2.2 Scar Formation 
During the inflammatory phase the original extracellular matrix is degraded in order to 
facilitate inflammatory cell traffic. To ensure the integrity of the heart wall during this phase 
a provisional matrix is formed. The initial plasma fibrin based structure is replaced by a 
more durable cellular-based fibronectin and hyaluronan matrix [47]. Cellular debris 
removal is accompanied by the infiltration of myofibroblasts, which start to extensively 
produce extracellular matrix proteins. Myofibroblasts also contract the newly formed 
collagen matrix, thus reducing the area and strengthening the durability of the scar [48,49]. 
Scar maturation is characterized by the replacement of initial type III collagen with type I 
collagen, crosslinking of collagen fibers and clearance of the initially excessive amount of 
myofibroblasts [49,50]. Finally, the mature scar represents a vascularized tissue consisting 
mainly of a collagen based matrix with a small portion of cellular components, such as 
myofibroblasts, smooth muscle cells and residual cardiomyocytes [51,52]. 
4.1.3 Therapeutic Implications 
Although each of the above described phases and cellular components are necessary for 
the appropriate healing of myocardial infarction, they may lead to exaggerated expansion 
of the initial injury and adverse cardiac remodeling when spatially and timely unrestricted 
[10]. Uncontrolled neutrophil activation, for instance, leads to thinning of the infarct wall 
and consequently systolic heart failure [10,53]. Moreover, unlimited myofibroblast 
activation causes heart wall stiffening and diastolic heart failure [10,54]. 
For the further reduction of long term adverse outcome after myocardial infarction, the 
development of new therapeutic strategies is needed. Therapeutic targeting of the 
subsequent healing process holds a great potential for the prevention of post-infarction 
complications. However, current attempts to introduce such modulatory therapeutic 
interventions have failed [55], thus substantiating the need for a deeper understanding of 
the underlying molecular mechanisms.  
Introduction 
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4.2 Danger Associated Molecule Patterns (DAMPs) 
4.2.1 Definition 
It has long been known that ischemically damaged myocardium elicits a strong 
inflammatory reaction [56]. Historically, the mechanism, which links myocardial injury to 
activation of the immune system, was strongly debated because of the paradigm that the 
immune system is evolved to protect the host against external pathogens. In 1994, Polly 
Matzinger first described a concept which postulated that “the immune system does not 
care about self and non-self, that its primary driving force is the need to detect and protect 
against danger” (Figure 2) [57].  
 
Figure 2: Models for discrimination of antigens that elicit an immune response. 
The historically oldest model, how the immune response discriminates immunogenic versus non-
immunogenic substances, proposes recognition of self (set a) versus non-self (set b). Janeway 
offered a refined version, saying that the immune system recognizes specific patterns of non-self 
antigens, so called pathogen-associated molecular patterns (PAMPs) (set e+f). Matzinger proposed 
a model, where an immunogenic response is elicited by substances that induce stress or 
inappropriate cell death. Part of this group are self-antigens, which are mutations or molecules that 
are normally hidden from immune system (set c), environmental toxins (set d) and pathogens (set e). 
Set f is microorganisms that have PAMPs, but which are harmless (symbiotic bacteria). 
(SNS- self versus non-self; INS- infectious non-self)  
Taken from [58] with modifications. 
Matzinger’s model stated that an immune response can be triggered by self-molecules, 
which are exposed to immune system upon the tissue injury, in order to clear the debris 
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and prevent further injury. Thereby, the model offered a hypothesis for how the immune 
system might be activated in response to sterile injury, such as myocardial infarction. In 
line with this concept, Seong and Matzinger first used the term “damage associated 
molecular pattern” (DAMP) in 2004,  describing immunogenic properties of hydrophobic 
portions of molecules, irrespective of their origin from pathogens or the organism itself [59].  
In 2005, Joost Oppenheim and De Yang proposed a classification where all DAMPs are 
divided into two groups: 1) pathogen-associated molecular patterns (PAMPs), 
representing molecules of microbial or viral origin, which elicit an immunogenic response, 
and 2) alarmins, endogenous molecules that signal tissue injury (Figure 3A) [60,61]. To 
date, two additional modifications of this concept are commonly used. They employ the 
term “DAMP” strictly for endogenous self-derived immunogens, whereas pathogen-
derived immunogens (PAMPs) are separate. In the first one, DAMPs are further divided 
into three subcategories. The first subgroup covers intracellular proteins, which are 
passively released from dying cells. The second subcategory encompasses damaged or 
modified extracellular matrix fragments. The third subcategory are alarmins, which denote 
cytokine-like molecules that are stored in cells and released upon cellular stress or lysis 
(Figure 3B) [62,63]. The second classification uses DAMPs and alarmins as synonyms 
[64,65] (Figure 3C).  
 
Figure 3: Three different classifications of antigens according to their origin. 
(A) Oppenheim’s and Yang’s classification uses DAMPs as an umbrella term for PAMPs 
(immunogens from bacteria and viruses) and alarmins (endogenous danger signals) [60]. (B) DAMPs 
are used as an umbrella term for passively released intracellular proteins, modified or damaged 
extracellular matrix, or alarmins (cytokine-like proteins, which are stored in cells and quickly released 
upon cellular stress) [62,63]. (C) DAMPs and alarmins are used as synonyms [64,66]. 
(DAMP- damage associated molecular pattern, PAMP- pathogen associated molecular pattern, ECM- 
extracellular matrix) 
Since there is no unified nomenclature, immunogenic molecules that signal tissue damage 
after myocardial infarction will be denoted as "DAMPs" in this thesis. 
Introduction 
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4.2.2 Pattern Recognition Receptors (PRRs) 
DAMPs signal through pattern recognition receptors (PRRs), expressed by immune cells, 
like dendritic cells and macrophages, and non-immune cells, such as fibroblasts, smooth 
muscle cells and endothelial cells  [67–70]. PRRs can be localized on the extracellular 
membrane as well as in the intracellular compartment [71]. On the extracellular membrane 
are localized groups of toll-like receptors (TLR), C-type lectin receptors (CLR) and various 
ungrouped receptors, like the receptor for advanced glycation end products (RAGE) or 
interleukin 1 receptors (IL1R). In the intracellular compartment, danger molecules are 
captured by nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and 
retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) [62,67,71]. 
4.2.3 Toll-Like Receptor 4 (TLR4) 
TLR4 is the most abundant toll-like receptor in the heart [72]. It can capture ligands both 
at the cell surface level or from endosomes [73,74]. The signal transduction  is ensured 
via two pathways that are determined by different recruited adaptor proteins: MyD88 and 
TRIF [75]. At the plasma membrane TLR4 triggers activation of the MyD88-dependent 
pathway that leads to an increase of inflammatory cytokine production [76]. TRIF-
dependent pathway is activated upon endocytosis of TLR4. It further induces inflammatory 
cytokine and type I interferon production [76,77]. It has been suggested that endosomal 
acidification is essential for the ligand binding and recruitment of TRIF adaptor protein to 
TLR4 in endosomes [78]. Moreover, stimulation of TLR4 augments the TGFβ-mediated 
fibrotic response in murine and human skin fibroblasts [79]. In murine hepatic stellate cells, 
the TLR4-triggered fibrotic response has been reported to be mediated via MyD88 by 
enhancing TGFβ signaling through downregulation of its pseudoreceptor Bambi [80].  
In the setting of myocardial infarction, TLR4 stimulation has been demonstrated to have 
divergent effects. Lipopolysaccharides (LPS) are classical ligands for TLR4 [67]. 
Pretreatment of rats with LPS has been reported to reduce the size of infarction and 
subsequent cardiac dysfunction after ischemia/reperfusion [81]. In ischemia/reperfusion of 
isolated rat hearts, the protective properties of LPS become apparent after 12 hours of 
pretreatment. The beneficial effect is abrogated by the protein synthesis inhibitor 
cycloheximide [82], thus indicating cardioprotective properties for the proteins that are 
produced upon the stimulation with LPS. On the other hand, TLR4 deficiency improves 
cardiac function without affecting infarct size, reduces inflammatory cytokine expression 
and interstitial fibrosis in remote myocardium after permanent coronary ligation in mice 
[83]. In an ischemia/reperfusion model, TLR4 deficiency reduces the size of infarct and 
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inflammatory cytokine expression [84,85], however, without improving cardiac function 
[85].  
MyD88 serves as a downstream adaptor protein for interleukin 1 and 18 and all toll-like 
receptors, except TLR3 [86–88]. Interestingly, induction of ischemia/reperfusion in MyD88-
deficient mice results in decreased size of infarction, improved cardiac function and 
attenuated neutrophil recruitment in comparison to wild type controls. However, MyD88 
deficiency has no impact on infarct size or cardiac function when ischemia/reperfusion is 
induced in isolated hearts [89]. Impeded recruitment of neutrophils and decreased size of 
myocardial infarction after ischemia/reperfusion can be influenced by MyD88 deficiency in 
the bone marrow [90], pointing out the differences between local cardiac PRR and 
systemic PRR signaling. 
4.2.4 DAMPs after Myocardial Infarction 
Recognition of DAMPs by PRRs represents the initial signaling event of tissue damage 
after myocardial infarction [91]. Several groups of DAMPs have been demonstrated to 
contribute to myocardial inflammation in the infarcted heart, including S100 proteins, heat 
shock proteins, high mobility group box 1 protein (HMBG1) and interleukin 1α [91,92]. 
DAMPs often do not display receptor specificity, so that one molecule can bind several 
PRRs. For example, HMGB1 signals through TLR4 [93], but also through TLR2 [94], TLR9 
[95] and RAGE [96]; S100A8/9 binds to TLR4 [97], but also to RAGE [98]. 
HMGB1 is one of the best characterized DAMPs and therefore often referred to as a 
prototype [99]. HMGB1 is a nuclear non-histone DNA binding protein. In the nucleus it is 
involved in gene transcription and DNA stabilization [92]. It is released from necrotic cells, 
but not from apoptotic cells, and elicits a pro-inflammatory response [100]. Additionally, 
HMGB1 has been reported to be secreted from murine macrophages and human 
monocytes upon exposure to LPS [101,102]. When directly injected into the heart, HMGB1 
triggers inflammatory cell infiltration, which is abrogated in TLR4 deficient mice [63]. The 
pro-inflammatory activity of HMGB1 depends on the extracellular redox milieu. It loses its 
cytokine activity upon oxidation of its cysteine residues [103]. In the setting of a myocardial 
infarction, HMGB1 has been reported to have opposing effects. After permanent coronary 
artery ligation, heightened HMGB1 release from HMGB1 overexpressing mice leads to 
smaller infarct size, improved cardiac function and increased vascularization [104]. In the 
model of ischemia/reperfusion, however, inhibition of HMGB1 reduces infarct size and 
improves cardiac function. The detrimental effect of HMGB1 is mediated in a RAGE-
dependent manner [96].  
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S100A1 has recently been described as a cardiovascular DAMP, which is rapidly released 
from cardiomyocytes upon myocardial infarction [64,105]. When directly injected in the 
heart, S100A1 elicits increase of pro-inflammatory ICAM1 and anti-inflammatory 
thrombospondin 2 expression, simultaneously suppressing collagen 1 expression. In the 
model of ischemia/reperfusion in mice, the inhibition of extracellular S100A1 leads to 
increased infarct size and worsened cardiac function. Of note, TLR4 has been identified 
as a receptor for extracellular S100A1 without any evidence of parallel signaling through 
RAGE [64]. 
The initial alarming about myocardial injury is ensured by DAMPs that bind to pattern-
recognition receptors. Targeting the DAMPs/PRR system, in vivo experiments in rodents 
have so far revealed divergent effects on the healing cascade after myocardial infarction. 
Further studies are required in order to delineate the effect of diverse DAMPs/PRRs on 
myocardial and immune cells and the resulting impact on myocardial infarct healing.   
4.3 Cardiac Fibroblasts  
Fibroblasts are commonly defined as cells of mesenchymal origin that produce 
extracellular matrix proteins, including interstitial collagens, fibronectin and laminin 
[106,107]. They are widely distributed throughout the complete organism and have diverse 
transcriptional profiles that depend on the organ of origin [108]. 
Cardiac fibroblasts are among the most numerous cell types within the heart [109,110]. 
Together with endothelial cells, fibroblasts form the majority of the non-myocyte fraction 
within the myocardium [111,112]. Fibroblasts are embedded in a collagen-based network 
that surrounds cardiomyocytes [110]. Cell-matrix organization and fibroblast content differs 
among different regions of the heart [107]. In the ventricles cardiomyocytes are organized 
in layers, which are enveloped by connective tissue and fibroblast sheets [113]. In the 
sinoatrial node, the pacemaker region of the heart, fibroblasts are more abundant, and the 
cell-matrix network is less organized than in the ventricles [107].  Besides surrounding 
pacemaker myocytes, fibroblasts also form islands of themselves [114].  
Under physiological conditions fibroblasts ensure the structural integrity of the heart by 
governing extracellular matrix turnover [109]. In addition to its structural role, connective 
tissue, which is produced by fibroblasts, also serves as an electrical insulator [115], 
thereby maintaining the electrical properties of the myocardium. Fibroblasts are known to 
express several gap-junction proteins, like connexin 40, 43 and 45 [109], although the 
precise role of fibroblasts in the electrical coupling of myocardium has yet to be defined 
[116]. Due to their close proximity to cardiomyocytes [117] and  lower vulnerability to 
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injurious factors [118], fibroblasts are often referred to as “sentinel cells" of the myocardium 
[106]. 
4.3.1 Cardiac Fibroblasts in Myocardial Infarction 
Cardiac fibroblasts actively participate in the healing process after myocardial infarction. 
To date, the best described form of cardiac fibroblast activation upon myocardial infarction 
is their transform into a myofibroblast phenotype, which ensures scar tissue formation 
[119,120]. In mice, myofibroblasts appear on day 4 after infarction and peak on day 7 [23]. 
In electron micrographs of the myocardium, cardiac fibroblasts are elongated cells with 
sheet-like extensions, whereas myofibroblasts are notably larger cells with multiple 
membrane processes and a high amount of exocytotic vesicles [116,117]. A classical 
marker for myofibroblasts is α smooth muscle actin (αSMA) [121]. The current model of 
fibroblast activation includes the transformation into a proto-myofibroblast, which further 
transforms into a mature myofibroblast (Figure 4) [48,106,122]. 
 
Figure 4: In vitro differentiation of cardiac myofibroblasts.  
Mechanical tension and TGFβ initiate the fibroblast transformation into αSMA expressing proto-
myofibroblasts. Further stimulation with TGFβ and/or retained mechanical tension results in the 
formation of fully differentiated myofibroblasts, which express high amounts of αSMA. Myofibroblasts 
produce various cytokines/chemokines, MMPs/TIMPs and AngII. Nonetheless, their most distinct 
feature is the prominent production of extracellular proteins, in particular collagens. Withdrawal of 
activating stimuli results in proto-myofibroblast de-differentiation into fibroblasts. In contrast, 
myofibroblasts are terminally differentiated cells that cannot convert back to proto-myofibroblasts or 
fibroblasts. 
(αSMA- alpha smooth muscle actin, TGFβ- transforming growth factor beta, AngII- angiotensin II, 
MMP- matrix metalloproteinase, TIMP- tissue inhibitor of metalloproteinase, ECM- extracellular 
matrix) 
Adapted from [48,106,122]. 
In 2014, Driesen and colleagues demonstrated the course of cardiac fibroblast 
differentiation into myofibroblasts in a cell culture model.  Cardiac fibroblasts transformed 
into proto-myofibroblasts upon mechanical tension and/or TGFβ stimulation. Fibroblasts 
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were αSMA negative and possessed high proliferative capacity, whereas proto-
myofibroblasts were αSMA positive with a decreased proliferative capacity. Further TGFβ 
stimulation and maintained mechanical tension resulted in mature myofibroblast formation 
that was characterized by prominent αSMA staining and the lack of proliferative capacity. 
With removal or blocking of the activating stimuli proto-myofibroblasts but not 
myofibroblasts were able to de-differentiate back to fibroblasts. On the protein level, 
myofibroblasts were secreting an increased amount of collagen, tissue inhibitor of 
metalloproteinases 1 (TIMP1), and chemoattractant CCL2. In contrast, fibroblasts were 
characterized by a prominent secretion of interleukin 10 (IL10). Proto-myofibroblasts 
secreted more collagens than fibroblasts, but less than myofibroblasts. Importantly, 
cardiac fibroblasts, grown in stiff plastic cell culture dishes and in serum enriched medium, 
developed a proto-myofibroblast phenotype spontaneously, resulting from mechanical 
tension from the plastic surface and the presence of TGFβ in fetal calf serum [122]. 
TGFβ elicits fibroblast differentiation into myofibroblasts, which produce various cytokines 
and a high amount of collagens [106,122–124]. In a model of dermal fibroblast and 
keratinocyte co-culture, keratinocyte-derived interleukin 1 (IL1) has been shown to inhibit 
TGFβ-mediated formation of myofibroblasts by activating nuclear factor κB (NFκB) 
transcription factors in fibroblasts. Although a notable amount of TGFβ has been found 
after 24 hours of co-culture, the myofibroblast phenotype was not observed before day 4 
[125].  
In the setting of myocardial infarction, IL1 is reported to be involved in the initiation and 
amplification of the inflammatory response [126]. In cell culture, IL1β is able to inhibit and 
reverse cardiac fibroblast differentiation into proto-myofibroblasts. This has been 
suggested as a potential endogenous control mechanism for the restriction of premature 
activation of myofibroblast differentiation after myocardial infarction in vivo [127–129]. 
Interestingly, IL1 also induces an increase in the production of inflammatory adhesion 
molecules and chemokines in cardiac fibroblasts [130,131].  
4.3.2 DAMPs and Cardiac Fibroblasts 
The signaling of sterile tissue injury is ensured by DAMPs that are sensed by various cell 
types, resulting in the initiation of an inflammatory response. Stimulation with HMGB1 
induces the expression of pro-inflammatory cytokines in cardiac fibroblasts and, to a lesser 
extent, also in myofibroblasts, thus demonstrating cardiac fibroblasts as potential sensors 
of DAMPs and active participants in the inflammatory phase. HMGB1 does not trigger 
fibroblast transformation into myofibroblasts. Notably, fibroblasts express significantly 
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more RAGE, which is one of the receptors for HMGB1, than myofibroblasts [132]. When 
treated with S100A8/9 [133], the most significantly upregulated function in cardiac 
fibroblasts is chemokine activity, as assessed by transcriptome analysis [134].  
In conclusion, cardiac fibroblasts have been shown to be critically involved in the scar 
formation phase after infarction. Additionally, fibroblast phenotype modulation by DAMPs 
seems to represent a key event for the initiation of an inflammatory reaction. Further 
research will have to reveal how the immune response after infarction is modulated by 
DAMP-stimulated cardiac fibroblasts. 
4.4 S100A1 
S100A1 is a member of the S100 protein family that consists of small (9-13 kDa) Ca2+ 
binding proteins, which participate in various intracellular activities [135,136]. Members of 
the S100 protein family have been reported to have cytokine-like functions in extracellular 
space, although it is not clear, if they can be actively secreted or only passively released 
from damaged cells [137,138]. Homodimers are  the preferential form of oligomerization 
for S100 proteins [135]. The homodimer of S100A1 can bind four Ca2+ ions. This leads to 
the exposure of a hydrophobic pocket that represents a binding site for target proteins 
[139,140] (Figure 5).  
 
Figure 5: Conformational changes of S100A1 upon Ca2+ binding. 
The binding of Ca2+ results in conformational changes of the S100A1 dimer. It opens a hydrophobic 
pocket that interacts with target proteins. α3 and α3’ helices (blue) rotate 90˚, exposing highly 
bioactive hydrophobic residues on α3 and α4 helix and α3’ and α4’ helix, as well as on the hinge 
region between α2 and α3 helices and between α2’ and α3’ helices.  
Taken from [140] with modifications. 
S100A1 protein is most abundant in muscle tissues, with the highest amounts found in the 
heart. In lower quantity, it is also found in other organs, like brain, kidneys and skin [141]. 
In the heart, S100A1 is mainly localized in the left ventricle, predominantly in 
cardiomyocytes. So far, no S100A1 expression has been detected in cardiac fibroblasts 
[64,142,143].  
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4.4.1 S100A1 in Cardiomyocytes 
S100A1 is involved in all major intracellular Ca2+ handling events within cardiomyocytes. It 
interacts with proteins of sarcoplasmic reticulum, myofilaments, and mitochondria (Figure 
6). 
 
Figure 6: Target structures and functions of S100A1 in cardiomyocytes. 
During diastole, S100A1 increases sarcoplasmic reticulum Ca2+ load by enhancing SERCA2A-
mediated Ca2+ uptake from the cytosol and by preventing Ca2+ leakage through RYR2. S100A1 also 
decreases the stiffness of the sarcomere protein titin, thereby facilitating diastolic relaxation. Within 
the mitochondria S100A1 enhances ATP production. 
(LTCC-L-type calcium channel, NCX-sodium-calcium exchanger, ATP-adenosine triphosphate, SR-
sarcoplasmic reticulum, SERCA2A-sarcoplasmatic reticulum Ca2+ ATPase 2a, PLB-phospholamban, 
RYR2-ryanodine receptor 2, EC coupling-excitation-contraction coupling)  
Taken from [144] with modifications. 
S100A1 binds to sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2A) and enhances its 
capacity to transfer Ca2+ from cytosol to the sarcoplasmic reticulum [145]. During diastole, 
the binding of S100A1 to RYR2 protects from arrhythmogenic Ca2+ leakage from the 
sarcoplasmic reticulum [146,147]. S100A1 also improves mitochondrial ATP production 
[148] and reduces passive stiffness of titin [149]. The execution of various S100A1 
dependant processes in myocardium is ensured with the total amount of approximately 2 
μg/mg of S100A1 protein within the heart [141].  
4.4.2 Extracellular S100A1 
The effect of extracellular S100A1 has been investigated in neuronal, pulmonary, and 
cardiovascular systems [135,150–152]. Chicks that received an intracerebral injection of 
S100A1-neutralizing antibody developed amnestic disorders, as measured by the 
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decreased retention of an aversive experience [153]. In mouse neuroblastoma cells, 
extracellular S100A1 activates NFκB and enhances neurite outgrowth in a RAGE 
dependant manner [154]. In the same setting, S100A1 displayed toxic effects in 
concentrations higher than 1 μM [154].  A mixture of S100A1 and S100B was shown to 
induce apoptosis in the undifferentiated neural cell line P12, which is derived from the rat 
pheochromocytoma [155,156]. Recently it has been demonstrated that extracellular 
S100A1 is internalized by lung endothelial cells, where it interacts with endothelial nitric 
oxide synthase (eNOS), resulting in protection against TNFα induced apoptosis [151]. In 
neonatal cardiomyocytes, 2-deoxyglucose induced apoptosis is limited by extracellular 
S100A1 [157]. 
Upon myocardial infarction, S100A1 is rapidly depleted from human cardiomyocytes [105] 
and can be detected in the serum [64,141,158]. Although the kinetics of S100A1 serum 
levels resemble the time course of cardiac troponins [159], the diagnostic value of S100A1 
is limited by its non-cardiomyocyte specific expression pattern, since elevated serum 
values can also be found in skeletal muscle disorders [141].  
Most recently, extracellular S100A1 has been reported to be involved in the healing 
process after myocardial infarction. Systemic S100A1 inhibition with a neutralizing 
antibody results in larger size of infarction and worsened cardiac function after 
ischemia/reperfusion injury [64]. 
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Figure 7: Extracellular S100A1 effect on cardiac fibroblasts. 
(1) Upon myocardial infarction S100A1 is released from damaged cardiomyocytes. (2) Neighboring 
cardiac fibroblasts take extracellular S100A1 up by macropinocytosis. (3) and (4) Internalized S100A1 
binds to TLR4 in acidic endosomes and signals in a MyD88-dependent manner. (5) Stimulation with 
S100A1 elicits ERK1/2 and NFκB activation. (6) S100A1-induced signal transduction resulted in 
significant gene expression changes on mRNA and protein level.  
(TLR4- toll-like receptor 4, MyD88- myeloid differentiation primary response protein 88, ERK1/2- 
extracellular signal-related kinase 1/2, p65- nuclear factor κ B p65 subunit, col-1 – collagen 1, SMA- 
α smooth muscle actin, CTGF- connective tissue growth factor, MMP9- matrix metalloproteinase 9, 
IL10- interleukin 10, ICAM1- intercellular adhesion molecule 1, TNFα- tumor necrosis factor alpha, 
SDF1- stromal cell derived factor 1, TSP-2 - thrombospondin 2) 
Taken from [64] with modifications. 
It has been shown that S100A1 that is released from damaged cardiomyocytes is taken 
up by neighboring cardiac fibroblasts (Figure 7) [64]. In detail, S100A1 is immediately 
internalized in cardiac fibroblasts by macropinocytosis. Importantly, neither endothelial 
cells, smooth muscle cells, nor adult cardiomyocytes internalize extracellular S100A1. In 
cardiac fibroblasts, S100A1 binds to TLR4 in acidic endosomes and recruits cytoplasmic 
MyD88, resulting in activation of extracellular signal-related kinase 1/2 (ERK1/2) and NFκB 
transcription factors. On the level of gene expression, S100A1 triggers downregulation of 
αSMA and collagen 1, simultaneously increasing anti-inflammatory protein IL10 [160] and 
thrombospondin 2 (TSP2) [161], as well as inflammatory protein ICAM1 [162], stromal cell 
derived factor 1 (SDF1) [163] and TNFα [164] expression. Interestingly, administration of 
S100A1-neutralizing antibody prior ischemia/reperfusion injury results in abrogated 
expression increase of IL10 and ICAM1 that is accompanied with delayed TNFα 
expression increase.  
In summary, S100A1 is released from damaged cardiomyocytes upon myocardial 
infarction. Following rapid internalization, S100A1 activates a TLR4-MyD88-dependent 
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signal transduction cascade in cardiac fibroblasts, leading to decreased profibrotic 
markers, such as αSMA and col-1, and increased expression of immunomodulatory 
markers, for example, ICAM1, TNFα and IL10.  
4.5 Aims of the Study 
In myocardial infarction, cardiac fibroblasts have traditionally been linked with the phase 
of scar formation, during which they transform into myofibroblasts and extensively produce 
extracellular matrix proteins. However, there is growing evidence that fibroblasts rapidly 
respond to infarction-related DAMPs, suggesting an active role in the inflammatory phase 
after myocardial infarction. S100A1 has been shown to be released into the interstitial 
space from ischemic cardiomyocytes and rapidly internalized by cardiac fibroblasts. In a 
cell culture model, extracellular S100A1 initiates a distinct signal transduction cascade, 
resulting in downregulation of αSMA and collagen 1 and increased expression of IL10 and 
ICAM1. This cardiac fibroblast phenotype might play a key role in the initiation of immune 
response to myocardial infarction.  
Therefore, the aims of this study were: 
1) Systematic time-resolved characterization of the gene expression profile of cardiac 
fibroblasts upon exposure to extracellular S100A1.  
2) Comprehensive analysis of the proteomic profile that defines the S100A1-
stimulated cardiac fibroblast phenotype. 
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5 Materials and Methods 
5.1 Materials 
5.1.1 Equipment and Consumables 
Device/ instrument Manufacturer 
C1000 touch thermal cylcer Bio-Rad 
Centrifuges  
Heraeus Megafuge 40R 
Thermo Fisher 
Scientific 
Mikro 200 R Hettich 
Rotina 420 R Hettich 
Table top centrifuge Roth 
CFX96 Touch™ Real-Time PCR Detection 
System 
Bio-Rad 
Heating circulator HAAKE 
Incubator Heracell 150i with oxygen control 
Thermo Fisher 
Scientific 
Laminar flow hood 
Thermo Fisher 
Scientific 
Langendorf perfusion apparatus  Custom-made 
Magnetic stirrer with hot plate neoLab 
Magnetic stirring bars neoLab 
Microscope IMT-2 Olympus 
Microscope IX81S1F-3 Olympus 
MyiQ™ Single-Color Real-Time PCR Detection 
System 
Bio-Rad 
Neubauer cell counting chamber Marienfeld-Superior 
pH meter  WTW 
Pipette controller accu-jet® pro  BRAND 
Pipette Eppendorf 
Peristaltic pump Ismatec 
Scale KERN 
Scissors, fine tip forceps, surgical forceps, 
bulldog clamp 
Fine Science Tools,       
B Braun 
Spectrophotometer Multiskan Spectrum 
Thermo Fisher 
Scientific 
Spectrophotometer NanoDrop 2000  
Thermo Fisher 
Scientific 
Pump for cell culture NeoLab 
Vortex IKA 
Water bath Memmert 
 
Consumables Manufacturer 
Cell culture 6-well plates Greiner Bio-One 
Cell culture flasks, T75, T175 Sarsted 
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Clear bottom 96-well plates 
Thermo Fisher 
Scientific 
Cell strainer  
24mm Netwell™ insert with 440 µm 
mesh size polyester membrane, sterile 
Corning 
Amicon Ultra-2 Centrifugal Filter Unit with 
Ultracel-3 membrane 
Merck Millipore 
Adhesive seals, optical Bio-Rad 
RNAase clear 0.5, 1.5, 2 mL tubes, PCR plates nerbe plus 
1.5 mL tubes Sarsted 
15, 50 mL tubes Greiner Bio-One 
Plastic Pasteur pipettes BRAND 
Serological pipettes Greiner Bio-One 
Pipette tips with filters Sarsted 
Reagent reservoirs, 50 mL Corning 
Sterile vacuum filtration system Stericup Merck Millipore 
Syringes, needles BD 
 
5.1.2 Materials for Cell Isolation, Culturing and Stimulation 
Chemical Catalog number Manufacturer 
Butanedione monoxime (BDM)  B0753 Sigma-Aldrich 
CaCl2∙2H2O C7902 Sigma-Aldrich 
(±) Carnitine hydrochloride C9500 Sigma-Aldrich 
Creatine C3630 Sigma-Aldrich 
EDTA tetrasodium salt ∙2H2O E6511 Sigma-Aldrich 
D (+) Glucose G7021 Sigma-Aldrich 
HEPES H4034 Sigma-Aldrich 
KCl P5405 Sigma-Aldrich 
Mercaptopropionylglycin M6635 Sigma-Aldrich 
MgSO4 M2643 Sigma-Aldrich 
Na-Pyruvat P5280 Sigma-Aldrich 
Na-Acetate S5636 Sigma-Aldrich 
NaCl S5886 Sigma-Aldrich 
Na-Glutamate G5889 Sigma-Aldrich 
NaHCO3 S5761 Sigma-Aldrich 
NaOH 106498 Merck Millipore 
Phenol Red sodium salt P5530 Sigma-Aldrich 
Taurine T8691 Sigma-Aldrich 
Water, CHROMASOLVPlus, 
for HPLC 
34877 Sigma-Aldrich 
 
Medium/ reagent/ additive Catalog number Manufacturer 
CLI095 (TLR4 inhibitor) tlrl-cli95 Invivogen 
Collagenase, type 2 CLS-2 Worthington  
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Dulbecco's Modified Eagle's 
Medium (DMEM) - high glucose 
D5796 Sigma-Aldrich 
Dulbecco's Phosphate Buffered 
Saline (PBS) 
D8537 Sigma-Aldrich 
Fetal Bovine Serum Superior 
(FCS) 
S0615 Biochrom 
Heparin Sodium, 25’000 I.U.    ratiopharm 
Insulin, 40 I.U./mL    Sanofi 
Penicillin-Streptomycin P4333 Sigma-Aldrich 
Human recombinant S100A1   
Self-produced, for 
detailed protocol 
see [64,165]  
Thiopental Sodium, 0.5 g   Inresa Arzneimittel 
Trypsin-EDTA (0.25%) 25200056 
Thermo Fisher 
Scientific 
 
5.1.3 Materials for Gene Knockdown by siRNA 
Reagent Catalog number Manufacturer 
Silencer® Select Negative 
Control No. 1 siRNA 
4390843 
Thermo Fisher 
Scientific 
TLR4, siRNA ID: s131044 4390771 
Thermo Fisher 
Scientific 
Lipofectamine® RNAiMAX 
Transfection Reagent 
13778075 
Thermo Fisher 
Scientific 
 
5.1.4 ELISA Kit 
Kit Catalog number Manufacturer 
Mouse/Rat CCL2/JE/MCP-1 
Quantikine ELISA Kit 
MJE00 R&D Systems 
 
 
5.1.5 Materials for Protein and RNA Isolation and qPCR 
Chemical/ reagent Catalog number Manufacturer 
Bromophenol blue 108122 Merck Millipore 
Chloroform 22711 VWR 
Dodecyl sulfate sodium salt 
(SDS) 
822050 Merck Millipore 
Ethanol 32205 Sigma-Aldrich 
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Glycerol solution 49781 Sigma-Aldrich 
iQTM SYBR Green Supermix  170-8884 Bio-Rad 
iScriptTM cDNA Synthesis Kit  1708891 Bio-Rad 
Isopropanol  33539 Sigma-Aldrich 
Polyacryl carrier   PC152 MRC 
TRIS- HCl T5941 Sigma-Aldrich 
TRIzol® Reagent  15596-026 
Thermo Fisher 
Scientific 
Water for molecular biology, 
DEPC- treated and sterile 
filtered  
95284 Sigma-Aldrich 
2- Mercaptoethanol 805740 Merck Millipore 
 
Gene symbol, primer assay 
name Catalog number Manufacturer 
Ccl2, Rn_Ccl2_1_SG QT00183253 Qiagen 
Tlr4, Rn_Tlr4_1_SG QT00387184 Qiagen 
 
Gene 
symbol 
Forward primer Reverse primer 
18s GTAACCCGTTGAACCCCATT GGCCTCACTAAACCATCCAA 
 
5.1.6 Materials Used by Dr. Martin Busch 
Chemical/ reagent Catalog number Manufacturer 
Total RNA Purification Plus Micro 
Kit  
48500 Norgen Biotek 
 
   Gene 
symbol 
Forward primer Reverse primer 
HPRT1 CCAGCGTCGTGATTAGTGAT AGAGGGCCACAATGTGAT 
CCL2 GGTCTCTGTCACGCTTCTG TTCTCCAGCCGACTCATTG 
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5.2 Methods 
5.2.1 Isolation and Culturing of Adult Rat Cardiac Fibroblasts 
5.2.1.1 Preparation of Isolation and Perfusion Buffers 
All buffers for the isolation of adult rat cardiac cells were prepared in ion free water 
Chromasolv Plus (Sigma-Aldrich). pH values were adjusted with 1M NaOH. 
Table 1: Composition of the cell isolation and perfusion buffer. 
  M (mol/g) C (mM) g/L for 1L 
10x stock solution    
Sodium chloride (NaCl) 58.4 850 50 
Potassium chloride (KCl) 74.6 54 4 
Magnesium Sulfate (MgSO4) 120.4 41.5 5 
Na Pyruvat 110.0 50 5.5 
Sodium bicarbonate (NaHCO3) 84.0 200 16.8 
D (+) Glucose 180.2 115 20.7 
HEPES 238.3 200 47.7 
Na-Glutamate 169.1 254 43.0 
Na-Acetate 82.0 48.8 4.0 
Phenol Red sodium salt 376.4 0.5 0.2 
1x isolation buffer  
(supplemented on the day of 
isolation )            
BDM 101.1 10 1 
Creatine 149.2 4.4 0.66 
Taurine 125.2 30 3.75 
Mercaptopropionylglycin 163.2 4.9 0.8 
Perfusion buffer (isolation buffer+ 
EDTA)    
EDTA tetrasodium salt dihydrate 416.2 0.09 0.04 
On the day of isolation, perfusion and cell isolation buffers were prepared. The pH for the 
final solutions was adjusted to 7.3. 
5.2.1.2 Cell Culture Mediums 
Adult rat cardiac fibroblasts were cultured in high glucose DMEM, supplemented with 10% 
FCS and 1% penicillin/ streptomycin (10% FCS DMEM). Before stimulation cells were 
starved in the DMEM, containing 1% penicillin/ streptomycin (P/S) and 0% or 0.5% FCS, 
depending on the subsequent experiments.    
Adjusted to  
pH 7.3, sterile 
filtered, stored 
at 4°C 
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5.2.1.3 General Cell Culturing 
Cells were cultured in a humidified, 37˚C, 5% CO2 incubator. Cell culture work was 
performed under sterile conditions in a laminar flow hood.   
5.2.1.4 Cardiac Cell Dissociation 
Adult rat cardiac cells were isolated according to the protocol from Xu and Colecraft [166] 
with minor modifications. The rat heart was perfused with digestion buffer in the 
Langendorff technique, thus enabling dissociation of single cardiac cells (Figure 8). 
 
 
Figure 8: Adult rat heart cell isolation by enzymatic digestion in the Langendorff technique. 
(A) Adult rat heart was mounted on the cannula for the retrograde perfusion with digestion buffer 
through the coronary arteries.  
(B) The cardiac tissues were digested in the closed circular system.  
(C)  Heart cells were dissociated from digested connective tissues yielding at least 60% viable, rod-
shaped cardiomyocytes right after the isolation, thereby indicating sufficient enzymatic digestion. 
(Scale bar represents 200 μm) 
An adult male Wistar rat (250-350 g) was anesthetized with 1 mL Thiopental i.p. injection, 
35 mg/mL, until loss of hind limb toe pinch reflex (surgical anesthesia). Incision areas on 
the abdomen and thorax were sterilized with 70% ethanol and opened with lateral cuts by 
scissors. The heart was exposed and cut out with a large portion of the aorta and quickly 
placed into a 10 cm Petri dish with 80 mL of room temperature perfusion buffer, 
supplemented with 8 I.U./mL heparin. The aorta was slid onto the cannula of the 
Langendorff apparatus, and fixed with a bulldog clamp. Perfusion was started immediately 
with a drip rate of 100 drops/min. Filling of the coronary arteries was checked and 
evaluated in order to determine, if the heart was correctly positioned on the cannula. Then 
the clamp was replaced with a suture.  In order to remove residual serum traces and free 
Ca2+, the heart was washed with 70 mL of perfusion buffer, where the first 20 mL contained 
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8 I.U./mL heparin. During the wash step, the pulmonary vessels were tied, in order to 
increase the pressure within the coronary system.  
When 26 mL of perfusion buffer were left in the system, collagenase II solution was added, 
thereby composing the digestion buffer for the heart cell dissociation. 50 mg Collagenase 
II was dissolved in 14 mL of perfusion buffer and added to the residual buffer in the system, 
thus together making the concentration of Collagenase II 1.25 mg/mL. The exact 
concentration of collagenase II was adjusted for each lot separately, varying from 1 to 1.5 
mg/mL. Next the circulatory flow was established, and the heart was perfused with the drip 
rate of 60 drops/min, 37˚C, for 30 minutes. The perfusion was stopped, when the heart 
became flaccid and easily penetrable by fine tip forceps. 
A small beaker was filled with 15mL of digestion buffer from the perfusion system for the 
first round of cell dissociation. Simultaneously, the ventricles were cut off and placed into 
the beaker. A 50 mL tube was filled with additional 15mL of digestion buffer (to be used 
later for the second round of cell dissociation). The ventricles were minced into 
approximately 10 pieces with scissors. For the first round of cell dissociation the 
suspension was incubated in the water bath (37°C) for 3 minutes with gentle shaking. In 
order to facilitate the dissociation of the cells, the tissue pieces were gently triturated 5-7 
times with the plastic Pasteur pipette with shortened tip (opening 3-4 mm Ø), followed by 
additional 3 minutes incubation in the water bath. The whole suspension was triturated 6-
10 times before being filtered through a 440 μm cell strainer into a 50 mL tube. 15 mL of 
isolation buffer (perfusion buffer without EDTA) was added to the cell suspension, and the 
cell suspension was left at room temperature to settle. The rest of the tissues from the cell 
strainer was placed back into the beaker, and mixed with the previously collected 
additional 15 mL of digestion buffer for the second round of cell dissociation. The rest of 
the tissues were once again incubated twice in the water bath and filtered as described 
above. The resulting cell suspension from the second round of dissociation was similarly 
mixed with 15 mL of isolation buffer.  
5.2.1.5 Separation of Cardiac Fibroblasts   
For the isolation of cardiac fibroblasts, after the cell dissociation both portions of cell 
suspension were centrifuged for 1 minute at 50 g to pellet the cardiomyocytes. The 
supernatant was collected and centrifuged one more time for 5 minutes at 1000 g. The 
resulting pellets were pulled together by resuspending them in 20 mL 10% FCS DMEM, 
and transferred to T75 cell culture flask. After 2 hours, the attached cells were gently 
washed with PBS and fresh 10% FCS DMEM was added.  
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5.2.1.6 Culturing of Cardiac Fibroblasts 
Four days after isolation, cardiac fibroblasts reached 100% confluence in the T75 cell 
culture flask. For the subculturing cells were washed twice with PBS, 3 mL of trypsin- 
EDTA 0.25% was added and fibroblasts were incubated for 3 minutes at 37˚C. 
Subsequently, 25 mL of 10% FCS DMEM was added to cells and the resulting fibroblast 
suspension was transferred into the T175 cell culture flask. After 2-3 days the cells were 
split again into 6-well plates with 100 000 cells per well. After 24-36 hours when the 
confluence was around 60-80%, the fibroblasts were washed twice with PBS and culturing 
medium was replaced by serum deprived medium. Cells were starved for 24 hours before 
further stimulation (for the differences in the siRNA transfection protocol see 5.2.2 siRNA 
Transfection). All experiments were performed on passage 2 (P2) (Figure 9).   
 
Figure 9: Density of cardiac fibroblasts at the beginning of stimulation. 
At 60-80% confluence, fibroblasts were serum starved for 24 hours before further stimulation. (Scale 
bar represents 200 μm) 
5.2.2 siRNA Transfection 
For the TLR4 siRNA knockdown, adult rat cardiac fibroblasts were plated on 6-well plates, 
100 000 cells per well. After 24-36 hours, when the confluence reached 60% (Figure 10), 
the cells were washed 1x with PBS and 1.5 mL of 0% FCS DMEM per well was added.  
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Figure 10: Density of adult rat cardiac fibroblasts before siRNA transfection. 
For the optimal knockdown results, transfection with siRNA was performed at ~60% confluence. 
(ACF, scale bar represents 200 μm) 
Transfection was performed with Lipofectamine RNA iMax Reagent according to the 
manufacturer’s protocol. For one well 250 μL of DMEM without any supplementation was 
mixed with 5 μL of Lipofectamine and shortly vortexed. 10 μL of siRNA (stock solution of 
10 μM, and final concentration of 50 nM per well) was added to 250 μL of DMEM without 
supplementation and shortly vortexed. 250 μL of transfection reagent mix was transferred 
to 250 μL of siRNA dilution, shortly vortexed and incubated at room temperature for 5 
minutes. Finally 500 μL of the siRNA reagent complex was added to each well, and the 
cells were incubated for 48 hours before further stimulation. The efficiency of TLR4 siRNA 
knockdown was assessed against negative control siRNA (scramble) knockdown using 
qPCR. 48 h after transfection cardiac fibroblasts were stimulated with 1 µM of recombinant 
S100A1 for additional 24 h.  
5.2.3 Enzyme Linked Immunosorbent Assay (ELISA) 
For the detection of rat CCL2 in the supernatant, the commercially available sandwich-
type ELISA kit was used according to the manufacturer’s protocol. Blank controls, 
standards, control of the assay and samples were added in duplicates to the wells of 
microplates that were pre-coated with CCL2 capture antibody. After 2 hours of incubation 
at room temperature, the wells were thoroughly washed and antibody against CCL2 
conjugated to horseradish peroxidase was pipetted into the each well. The plate was 
incubated once again for 2 hours at room temperature. Then the substrate solution was 
added. After 30 minutes of incubation at room temperature, protected from light, the stop 
solution was added, and the optical density was measured at the wavelength of 450 nm 
with correction wavelength set to 540 nm. The control value of the assay had to be in the 
range from 101 to 169 pg/mL. Detection range for the assay was 15.60- 1.000 pg/mL.   
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Correction optical density (540 nm) was subtracted from each data point. Subsequently, 
blank control (450 nm) was subtracted from each tested sample. For the calculation of the 
concentration of samples a 4-parameter logistic curve fit was created from OD and 
concentration values of  standards with the web-based application elysaanalysis.com 
[167]. Resulting formula was used for the calculation of the concentration of the samples. 
5.2.4 Isolation of RNA, Reverse Transcription, qPCR 
5.2.4.1 Isolation of Total RNA 
The total RNA from adult rat cardiac fibroblasts was isolated with TRIzol® Reagent 
according to the manufacturer’s instructions with minor changes. In brief, the supernatant 
from 6-well plates was collected or discarded, 1 mL of TRIzol® was added in each well 
and incubated for 2 minutes at room temperature. Samples were collected, and then 200 
μL of chloroform were added and mixed by vigorously shaking the tubes. For the phase 
separation, samples were centrifuged for 15 minutes at 18 000 g, 4˚C. From now on all 
steps were performed on ice. The upper aqueous phase that contains RNA was 
transferred to a new tube without disturbing the interphase or organic layer. In order to 
precipitate RNA, ice-cold 100% isopropanol and 1.5 µL of polyacryl carrier were added, 
then briefly mixed by inverting the tubes. After that, RNA was allowed to precipitate 
overnight at -20°C. To collect the RNA, the tubes were centrifuged for 15 min at 18 000 g, 
4˚C. The pellet was washed twice with ice cold 75% ethanol and air dried for approximately 
10 minutes and dissolved in 20 μL of DEPC-treated water. RNA quality and concentration 
were assessed with NanoDrop2000. 
For the RNA isolation of Dr. Martin Busch’s experiments Total RNA Purification Plus Micro 
Kit was used according to manufacturer’s instructions. 
5.2.4.2 Reverse Transcription 
Reverse transcription of the RNA was performed with iScript cDNA synthesis kit following 
the manufacturer’s protocol. 1 μg of RNA was mixed with 4 μL of iScript reaction mix and 
1 μL of reverse transcriptase. The volume was scaled up to 20 μL with DEPC-treated 
water. The reaction was performed with the following protocol: annealing- 5 minutes at 
25˚C, reverse transcription- 30 minutes at 42˚C, inactivation of the enzyme- 5 minutes at 
85˚C. The produced cDNA was stored at -20˚C until further use. 
5.2.4.3 Quantitative Real-Time PCR (qPCR) 
For the qPCR reaction, iQ SYBR Green Supermix was used according to the user manual 
for the final volume of 15 μL per reaction. 7.5 μL of iQ SYBR Green Supermix was mixed 
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with 1 μL of the forward and reverse primer mix (final concentration 300 nM each, or 
according to the primer data sheet for commercially available ones). The cDNA was diluted 
1:100 in DEPC-treated water. For one reaction 6.5 μL of diluted cDNA was used, resulting 
in 65 ng of cDNA per run. The qPCR was performed on Biorad MyIQ PCR cycler with the 
protocol, described in the Table 2. 
Table 2: Protocol for qPCR. 
Number of Cycles Temperature Dwell time Step 
1x 95°C 03:00 Denaturation 
 95°C 00:10 Denaturation 
40x 60°C 00:45 Annealing 
  72°C 00:30 Elongation 
1x 95°C 00:05 Termination 
1x 55°C 01:00 
Temperature 
gradient set 
point 
80x 55→95°C, 0,5°C/increment  00:10 Melting curve 
1x 4°C ∞ Hold 
    
Dr. Martin Busch used iQ SYBR Green Supermix according to the user manual for the final 
volume of 20 μL per reaction. 10 μL of iQ SYBR Green Supermix was mixed with 1 μL of 
the forward and reverse primer mix (final concentration 250 nM each). 50 ng of cDNA was 
used per run, diluted in 2 μL of water. The total volume was scaled up to 20 μL with 7 μL 
of water. The qPCR was performed on CFX96 Touch™ Real-Time PCR detection system 
with the protocol, described in the Table 3. 
Table 3: Protocol for qPCR, Dr. Martin Busch’s experiments 
Number of 
Cycles 
Temperature 
Dwell 
time 
Step 
1x 95°C 03:00 Denaturation 
40x 
95°C 00:15 Denaturation 
60°C 01:00 
Annealing, 
elongation 
1x 95°C 01:00 Termination 
80x 
55→95°C, 
0,5°C/increment  
00:05 Melting curve 
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18s was used as a reference gene (for the Dr. Martin Busch’s experiments- HPRT1). 
Relative gene expression changes were calculated applying ΔΔCt method according to 
Livak and Schmittgen [168] with the following formula: 
fold change=2
-∆∆Ct 
-∆∆Ct= -((CtGOI- Ct18s)treatment - (CtGOI- Ct18s)control) 
Ct- threshold cycle, GOI- gene of interest. 
5.2.5 Transcriptome 
In order to evaluate gene expression changes in cardiac fibroblasts in response to 
extracellular S100A1, serial transcriptome analysis was performed using microarray 
technology. Adult rat cardiac fibroblasts were starved for 24 hours in 0.5 % FCS DMEM 
(6-well plates, 2 mL of medium per well). For each time point a separate plate was 
prepared. Cells were stimulated with recombinant S100A1 for 1, 2, 4, 6, 8, 12, 18, 24 and 
48 hours. Unstimulated control samples were collected before stimulation ("0 hours") and 
at each indicated time point. RNA was isolated with TRIzol® Reagent as described above. 
The total amount of 1 μg was submitted to the DKFZ Genomics and Proteomics Core 
Facility. RNA quality control was performed on an Agilent 2100 Bioanalyzer. Gene 
expression profiling was performed with Affymetrix GeneChip® Rat Gene 2.0 ST Array. 
The sample preparation for the hybridization on the arrays was carried out with the 
GeneChip® WT PLUS Reagent Kit (Affymetrix), according to the manufacturer’s 
instructions. In brief, 200 ng of total RNA was used for the synthesis of the cDNA, which 
was further transcribed and amplified into cRNA. Next, single-stranded cDNA (ss-cDNA) 
was synthesized from cRNA, followed by fragmentation and biotinylation.  Finally, 5.5 µg 
of  fragmented and biotin-labeled ss-cDNA were hybridized for 17 h at 45°C on arrays with 
GeneChip® Hybridization, Wash and Stain Kit in automated system Fluidics Station 450 
(both from Affymetrix). The scanning of gene microarray was done with a 
GeneChip® Scanner 3000 (Affymetrix).  
The obtained data was processed in collaboration with Dr. Dr. Melanie Börries and Dr. 
Hauke Busch (Institute of Molecular Medicine and Cell Research, University of Freiburg). 
The functional enrichment analysis was performed with Gene Set Enrichment Analysis 
software [169,170].  
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5.2.6 Secretome 
5.2.6.1 Sample Preparation and LC-MS/MS Data Acquisition 
For the identification of secreted protein pattern by cardiac fibroblasts upon extracellular 
S100A1 stimulation secretome analysis was performed. Supernatant from stimulated and 
untreated cells was prepared as follows. Adult rat cardiac fibroblasts in 6-well plates were 
starved for 24 hours in 0% or 0.5% FCS DMEM, 2 mL per well. 1 mL of medium was 
aspirated from each well before stimulation with 1 μM recombinant S100A1. After 48 hours 
of incubation supernatant was collected. For the protein concentration an Amicon 
ultracentrifugation filter device (3 kDa pore size) was used according to the manufacturer’s 
instructions. One mL of supernatant was added in the filter device and centrifuged for 110 
minutes at 4000g, 8˚C using swinging bucket rotor. As a result one mL of supernatant was 
concentrated to 60 μL. In order to collect the concentrated supernatant in the collection 
tube, the reservoir of the filtrate was discarded, filtration device was inverted and 
centrifuged for 2 minutes at 1000g. 
30 μL of concentrated supernatant was mixed with 3 μL of loading buffer (300 mM TRIS-
HCl, 12% SDS, 0.3% Bromophenolblue, 60% glycerol, 12% β-mercaptoethanol). The 
further processing was done by the ZMBH Core Facility for Mass Spectrometry & 
Proteomics. After boiling for 3 minutes at 60˚C, samples were loaded into a 10% SDS 
acrylamide gel. The gel was run until the bromphenol blue front was about 2 cm into the 
well. Each lane was cut into four pieces according to their molecular size. Proteins in each 
piece were further digested with trypsin. The resulting peptides were labeled by reductive 
dimethylation, control samples being labeled as ‘light’ with mass increase of 28 kDa per 
primary amine and S100A1-treated samples as ‘intermediate’ with mass increase of 32 
kDa per primary amine. Then control and S100A1-treated samples from the same 
molecular size range were mixed together and subjected to liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) analysis with the Orbitrap Elite Hybrid Mass 
Spectrometer (Thermo Fisher Scientific). 
5.2.6.2 Identification and Sorting of Valid Secreted Proteins 
Protein identification performed Dr. Bernd Hessling with MaxQuant 1.5.2.8 software. 
Protein names and gene symbols were derived from the UniProt data base [171]. Data 
were sorted, marking common contaminants from sample preparation process (e.g. 
keratins, trypsin) and proteins of bovine origin, as well as false positive hits from decoy 
database.  
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The ratio of the treatment with S100A1 vs. control for each protein was calculated. In 
addition, the absolute amount of protein in the sample was determined with the absolute 
quantification (iBAQ) value. It represents the sum of intensities of detected peptides 
divided by the intensities of all theoretically obtainable peptides from the protein [172]. 
Ratios of the proteins were calculated from the intensities of peptides, which were detected 
both in control and S100A1 samples. iBAQ values were determined from the intensities of 
peptides, which were detected in the respective sample (Figure 11). 
 
Figure 11: Data sets for the calculation of ratios and iBAQ values of proteins. 
For the calculation of protein ratios from control vs. S100A1-treatment, only the intensities of peptides 
that were detected in both control and S100A1 stimulated samples were used (set b). The iBAQ value 
for each protein was determined from the intensities of all detected peptides for each samples: 
intensities from set b and c were used for the iBAQ value calculation of each protein from S100A1 
sample, whereas intensities of set a and b were used for the iBAQ value calculation of each protein 
from control sample. 
(iBAQ- intensity based absolute quantification) 
Further data processing, annotation and statistical analysis was performed with Perseus 
1.5.2.6 software (developed by group of Prof. Dr. Matthias Mann) with the assistance of 
Dr. Hessling. All values were logarithmically transformed and the median of triplicates was 
calculated, where appropriate. The data sets were reduced by excluding previously 
marked contaminants and false positive hits. To separate extracellular proteins from 
intracellular ones, filtering according to the UniProt identifier “gene ontology cellular 
compartment” (GOCC) was performed. Proteins annotated with one or more of the 
following GOCC names were included in downstream calculations: extracellular matrix, 
extracellular matrix part, extracellular membrane-bounded organelle, extracellular 
organelle, extracellular region, extracellular region part, extracellular space, and 
extracellular vesicular exosome.  
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5.2.6.3 Statistical Analysis and Biological Classification  
The significance of the upregulation or downregulation of the proteins was calculated with 
one-sample t-test, as an input matrix using protein ratios. The relative changes were 
expressed as a median of protein ratios from triplicates.  
Comparison and visualization of the protein composition from cell supernatants with or 
without FCS were performed with the web based application BioVenn [173]. In brief, the 
data sets of detected valid extracellular proteins from the 0% and 0.5% FCS groups were 
loaded into the software. The number of proteins was depicted as a Venn diagram that 
allows visualization of the groups of common proteins detected in both treatment 
conditions as well as proteins, detected only in one of the treatment condition.  
For the correlation analysis Pearson correlation was employed. It measures the strength 
of increasing or decreasing linear association between two variables that are normally 
distributed [174].  
Biological functions of the secretome were determined by grouping the proteins with one-
dimensional (1D) annotation enrichment analysis and Fisher’s exact test. Each protein was 
annotated according to its biological function, molecular function, cellular compartment 
and keywords from UniProt. Separate annotation category was created manually for 
distinct inflammatory proteins, and will be discussed in the Result section 6.2.4.  
1D annotation enrichment analysis was performed as described by Cox and Mann [175]. 
Enrichment of proteins from one biological category was tested with the two-sample 
Wilcoxon-Mann-Whitney test. This tests estimates, whether the category of interest ranks 
statistically significantly higher or lower comparing with the distribution of the whole group. 
For the multiple hypotheses testing Benjamini-Hochberg false discovery rate (FDR) was 
set to 2%. The input data were ratios or iBAQ values of each protein from the secretome. 
The enrichment of the category was expressed by positioning it in the overall distribution 
of data points. It was depicted as a position score, calculated as follows: 
s=
2×(R1-R2)
n
 
R1 was average rank of the input data from the group of interest, R2 was average rank of 
respective numerical items from the rest of the proteins and n was the total number of 
included proteins. 
Biological function enrichment analysis for upregulated proteins was performed with 
Fisher’s exact test. This test assesses, whether the non-random link between proteins 
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from predefined group exists. Within the computation proteins with ratios more than 4 were 
included. The Benjamini- Hochberg FDR was set to 2%. The enrichment of certain 
biological category was calculated with the following formula: 
enrichment factor=
intersection size
category size
×
total size 
selection size 
 
Intersection size represented proteins with the ratio more than 4 that belonged to the 
certain category, category size was the number of all detected extracellular proteins from 
the category of interest, total size was the number of all detected extracellular proteins and 
the selection size was the number of proteins, which ratio was more than 4. 
5.2.7 Statistics 
For the cell culture experiments, data were plotted as mean ± SEM, unless indicated 
otherwise. For comparison of two groups unpaired two-tailed Student’s test was used. For 
more than two groups one-way ANOVA was performed. Results were considered to be 
significant, if p<0.05. 
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6 Results  
Myocardial infarction results in a massive release of DAMPs [176–178]. They contribute 
to the activation of a systemic immune response that is needed for the clearance of cellular 
debris [10,92]. It has been demonstrated that HMGB1 and IL1α influence cardiac 
fibroblasts by increasing pro-inflammatory gene expression and suppressing their 
transformation into myofibroblasts [131,132]. S100A1 is a cardiomyocyte-derived DAMP, 
which is internalized by cardiac fibroblasts [179]. Within this study, the response of cardiac 
fibroblasts to stimulation with S100A1 was investigated.  
6.1 Gene Expression Profile of Cardiac Fibroblasts upon 
Stimulation with S100A1  
In cardiac fibroblasts, extracellular S100A1 triggers upregulation of several inflammation 
related genes and proteins, such as intercellular adhesion molecule 1 or interleukin 10. At 
the same time it downregulates collagen 1α1 and α smooth muscle actin production [64]. 
In order to understand the complex transformation of the fibroblast phenotype upon 
stimulation with S100A1, a time-resolved transcriptome analysis was performed. 
6.1.1 Principal Component Analysis of Time-Resolved Transcriptome  
In order to investigate the transcriptomic changes of S100A1-treated cardiac fibroblasts 
over time, cells were stimulated with recombinant S100A1 for 1, 2, 4, 6, 8, 12, 18, 24, and 
48 hours. After the acquisition of microarray data, intensities for each gene per time point 
were combined together for each experimental condition and principal component analysis 
was performed. All gene expressions per sample were reduced to two dimensions 
(principal components), which correspond to the greatest variances. With this approach it 
is possible to visualize the complete pattern of gene expression of a single sample as one 
point with two coordinates. The distance, which separates several probes from each other, 
is expressed in percentage and allows to assess the differences of transcriptome between 
several samples. Thereby, the impact of S100A1-treatment over time was evaluated by 
the calculation of principal components for each sample from control and stimulated 
groups. 
 As shown in Figure 12, treatment with S100A1 resulted in dynamic transcriptomic 
changes, which could be detected already at the early time points. At the 4 hour time point 
the gene expression pattern after the stimulation with S100A1 differed from the respective 
control sample by approximately 10% and 5% increase of principal component 2 (PC2) 
and principal component 1 (PC1), respectively. In the following time course, the S100A1-
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treated fibroblasts deviated further from their corresponding controls. After 24 hours, the 
stimulated sample was separated from the respective control by approximately 20% and 
5% increase of PC1 and PC2, respectively. At the final time point (48 hours) the S100A1-
treated sample decreased by 5% on PC2, comparing to 24 hours. Thus, in the last time 
point the control and S100A1-stimulated sample differed by around 20% of PC1, whereas 
according to PC2 they located roughly at the same level. It is important to note that the 
incubation of control samples for 48 hours had only a minor effect on the gene expression 
profile. The data points between 0 and 48 hours differed for approximately 5% on principal 
component 2 without any notable perturbations during the whole period of incubation. 
 
Figure 12: S100A1 elicits early gene expression profile changes in cardiac fibroblast with 
dynamic fluctuations over time. 
Principal component analysis of the serial transcriptome. Cardiac fibroblasts were stimulated with the 
S100A1 for 0, 1, 2, 4, 6, 8, 12, 18, 24 and 48 hours. After the data acquisition from gene microarray, 
the intensities of each sample were grouped together and plotted with respect to other samples. The 
greatest variances were calculated in 2 dimensions (principal components).  S100A1-treated 
fibroblasts showed early and dynamic fluctuations of the gene expression pattern over time. Starting 
from the 4 hours up to the final investigated time point the S100A1 stimulated samples strongly 
deviated from the gene expression profiles of earlier time points and respective controls. In contrast, 
the gene expression pattern of control samples had only minor changes over 48 hours of incubation. 
(ACF, n=1, S100A1 1μM, 0.5% FCS) 
Cardiac fibroblast stimulation with S100A1 led to an early shift of the gene expression 
profile that dynamically fluctuated over time, strongly deviating from the unstimulated 
samples. In the next step gene expression pattern changes were analyzed further by 
linking them with possible subsequent biological events. 
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6.1.2 Transcriptome-Derived Biological Functions  
The principal component analysis of the serial transcriptome revealed a prominent 
activation of cardiac fibroblasts with an alternating pattern of gene expression profile over 
time after the treatment with S100A1. For the evaluation of the biological events, which 
follow fibroblast stimulation, gene expression changes were sorted into categories of 
biological regulations and functions. 
Transcriptomic changes of cardiac fibroblasts upon treatment with S100A1 were analyzed 
with a Gene Set Enrichment Analysis (GSEA) software, identifying biological categories 
that significantly differed between control and treated samples. Since the control samples 
were collected after 1, 4, 12, 24 and 48 hours, these time points were taken for the 
calculation of the enriched biological functions. The intensity of regulation for each 
category per time point was obtained as an adjusted significance level, where the p-value 
was calculated for the enrichment of category that was normalized to the gene set size.  
For the adjustment of the p-value the permutation based false discovery rate was applied. 
The adjusted significance represents the probability that the enrichment of a given 
category is a false positive hit [169,180]. Higher relative differences for genes from 
particular category yields lower adjusted p-value. Note that the adjusted p value 0.05 
corresponds to 1.3 in –log10 scale. 
In Figure 13 significantly upregulated biological functions and pathways are shown, 
indicating a strong link between the stimulation with S100A1 and positive activation of 
inflammatory processes in cardiac fibroblasts. The category with the lowest adjusted p-
values was chemokine activity that was highly upregulated already at the one hour time 
point. The next most upregulated groups were categories of neutrophil chemotaxis and 
cellular response to tumor necrosis factor.  
From the intracellular signaling pathways the TLR4, ERK1/2 and NFκB signaling cascades 
were detected to be activated, albeit with less pronounced upregulation comparing to the 
highest ranked categories of chemokine activity or cellular response to tumor necrosis 
factor. It is in agreement with previous studies, where TLR4 has been identified as a 
receptor for recombinant S100A1, further signaling components being ERK1/2 and NFκB 
[64,181].  
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Figure 13: S100A1 triggers upregulation of inflammatory gene expression profile in cardiac 
fibroblasts. 
Significantly upregulated biological functions of the transcriptome from ACF after 1, 4, 12, 24 and 48 
hour stimulation with S100A1. Gene expression changes were clustered and annotated according to 
their biological functions with a gene set enrichment analysis (GSEA) software. The earliest and most 
prominently upregulated function were chemokine activity, cellular response to tumor necrosis factor 
and neutrophil chemotaxis. 
(ACF, n=1, S100A1 1μM, 0.5 % FCS) 
In the next step, calculation of the significantly downregulated categories was performed 
(Figure 14). Treatment of cardiac fibroblasts with S100A1 resulted in a decrease in the 
expression of genes, which are characteristics for the formation and function of 
myofibroblasts. Already at the 4 hour time point the category of extracellular matrix 
components was the most downregulated group. S100A1 stimulation also led to a 
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prominent suppression in the expression of genes, which are responsible for the stress 
fiber formation and cytoskeleton production, as well as for the collagen and collagen fibril 
organization. Besides the downregulation of various myofibroblast-related categories, 
according to the GSEA analysis S100A1 also suppressed mitosis related categories, for 
example, condensed chromosome kinetochore, chromosome segregation, and mitosis. 
However, the interpretation of the effect of S100A1 as an anti-mitotic and, therefore, anti-
proliferative might be misleading, because the list of upregulated functions included also 
the category of positive regulation of proliferation, and previous studies have demonstrated 
no effect of S100A1 on the proliferation of cardiac fibroblasts [64,182]. 
 
Figure 14: S100A1 stimulation leads to suppressed expression of extracellular matrix and 
cytoskeleton genes in cardiac fibroblasts. 
Significantly downregulated biological functions of the transcriptome from ACF after 1, 4, 12, 24 and 
48 hour stimulation with S100A1. Downregulated biological functions were calculated with GSEA.  
The earliest and most notably downregulated clusters of genes comprised categories of extracellular 
matrix and cytoskeleton.  
(ACF, n=1, S100A1 1μM, 0.5 % FCS) 
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In summary, the analysis of transcriptome from S100A1-treated adult cardiac fibroblasts 
revealed an early and notable upregulation of the immune response gene expression, 
particularly, chemokine activity. It was accompanied by the downregulation of the 
functional categories, which are related to the formation of extracellular matrix. The 
activation of immune response and suppression of extracellular matrix formation suggest 
a phenotype of cardiac fibroblasts, which resembles the response to other cardiovascular 
DAMPs, interleukin 1 and HMGB1. Both of them are shown to induce the cytokine 
production in cardiac fibroblasts without increasing or even suppressing the classical 
myofibroblast-related markers, such as collagens or αSMA [106,127,128,132].    
6.2 Characterization of S100A1-Evoked Pro-inflammatory 
Phenotype of Cardiac Fibroblasts on Protein Level 
The biological functions of the cell are driven by proteins [183]. The rate of their production 
may differ from the respective gene expression [172]. Therefore, in the next step the 
expression levels of proteins were investigated in order to verify the transcriptome data 
and further analyze the phenotype of cardiac fibroblasts upon stimulation with S100A1. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology was applied 
for protein detection. Since the most notable differences from the transcriptome analysis 
indicated changes in the production of secreted proteins, the secretome from cardiac 
fibroblasts was investigated further. The mass spectrometry-based analysis was 
performed on the supernatant from S100A1-treated and control fibroblasts. 
Proteins were considered for the further analysis, if identified with at least 2 peptides, from 
which at least one was uniquely assigned to the particular protein. After filtering out the 
contaminants and false positive hits 606 proteins remained. From them 380 proteins were 
annotated to be extracellular (see section 5.2.6.2). 319 and 326 extracellular proteins 
overlapped in all 3 biological replicates from control and S100A1 samples, respectively. 
316 extracellular proteins were detected in both control and S100A1-treated samples in 
all 3 biological replicates. Since mass spectrometry possesses high specificity, but relative 
low sensitivity [184–186], further analyses were performed with the set of all 380 proteins, 
thereby avoiding loss of proteins which might be missed in some experiments due to the 
limited power of detection. 
6.2.1 Significantly Regulated Secreted Proteins 
In order to visualize the effect of the stimulation with S100A1 on an individual secreted 
protein level, the relative fold change and significance for each protein were calculated by 
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one sample t-test. Proteins are depicted in a volcano plot (Figure 15), where red colored 
dots denote proteins with at least 2-fold (1 in log2 scale) upregulation and purple filled- at 
least 2-fold downregulation (-1 in log2 scale). For the separation between significantly and 
non-significantly regulated proteins, the threshold line for p value of 0.05 (1.3 in –log10 
scale) is shown. All significantly up- or downregulated proteins are located above the line. 
The full list of differently changed proteins from the volcano plot and their p-values is 
included in the Supplementary table 1. 
The volcano plot of single proteins revealed a marked effect of S100A1 on the relative 
increase of secreted proteins. Significantly downregulated proteins formed a numerously 
smaller group with less distinct fold changes between stimulated and unstimulated 
samples. 
Ranked according to relative changes, the highest upregulated proteins from significantly 
increased ones were lipocalin 2 (Lcn2), chitinase-3-like protein 1 (Chi3l1), complement C3 
and pentraxin 3 (Ptx3).  In case of downregulated proteins, collagen 8a1 (Col8a1), C-type 
lectin domain family 3, member B (Clec3b), and osteoglycin (Ogn) had the lowest ratios 
from the significantly changed proteins. 
The most prominently increased and significantly upregulated proteins possess various 
biological functions. Lipocalin 2 is reported to be involved in the attraction of neutrophils 
[187] and macrophage polarization into M1 phenotype [188].  In contrast, pentraxin 3 
impedes recruitment of neutrophils and macrophages [189], but also protects 
cardiomyocytes from ischemia/reperfusion injury [190]. C3a, which is the subunit of C3, 
induces T helper 1 response and degranulation of peripheral blood mononuclear cells 
[191]. However, in the setting of ischemia/reperfusion injury C3a also confines neutrophils 
within the bone marrow [192]. Chitinase-3-like protein 1 is reported to protect 
macrophages against oxidant-induced cell death [193]. Altogether, all the highest rated 
upregulated proteins according to the volcano plot possessed diverse functions that do not 
complement each other.  
The reported functions of the most downregulated from significantly regulated proteins 
correspond to the suppression of extracellular matrix formation. Collagen VIII is a structural 
component within the extracellular matrix [194] and osteoglycin takes part in its formation 
[195]. The functions of C-type lectin domain family 3, member B in the fields of cardiology 
or immunology are yet to be defined. This kind of functional suppression is consistent with 
the initially performed transcriptome analysis (see Section 6.1.2).  
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Figure 15: The profile of protein ratios indicates a prominent stimulatory and moderate 
suppressive effect of S100A1 on secreted proteins from cardiac fibroblasts. 
Volcano plot of p-values against the ratios of secreted proteins upon the stimulation with S100A1. 
Purple filled circles- at least 2-fold downregulated proteins, red filled circles- at least 2-fold 
upregulated proteins. The majority of differentially regulated proteins is upregulated. Relative fold 
changes of the upregulated proteins reach higher values, as compared to the downregulated ones. 
The highest ranked upregulated proteins are Lcn2, Chi3l1, C3 and Ptx3, whereas the most 
dowregulated significantly regulated proteins are Col8a1, Clec3b and Ogn. 
(ACF, n=3, S100A1 1μM, 48 h stimulation, 0% FCS, Lcn2- lipocalin 2, Chi3l1- chitinase-3-like protein 
1, C3- complement C3, Ptx3- pentraxin 3, Col8a1- collagen 8 A1, Clec3b- C-type lectin domain family 
3, member B, Ogn- osteoglycin) 
The sorting of proteins according to their fold change versus control and significance 
allows to assess the effect of S100A1. It demonstrated a prominent stimulatory and 
moderate suppressive impact on the relative ratios of secreted proteins from cardiac 
fibroblasts. Moreover, the volcano plot enabled visualization of the proteins, which might 
be responsible for the biological effect of the secretome from S100A1 stimulated 
fibroblasts.  However, the reported functions were not complementary for the proteins with 
highest significant relative changes. Therefore the biological activity of the secretome from 
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S100A1-treated cardiac fibroblasts was further analyzed by grouping proteins according 
to their biological functions.  
6.2.2 Correlation between Transcriptome and Secretome 
In order to analyze the link between gene expression changes and secreted proteins, 
relative fold changes from the transcriptome were correlated to the respective fold changes 
from the secretome. The differentially expressed mRNA translation into proteins may be 
delayed, the time lag between mRNA expression and protein production being 2-6 hours, 
when the correlation between gene expression and protein production are described to be 
the highest [196,197]. Since the protein secretion can potentially be even more delayed 
from the respective gene expression than protein production, the secretome analysis after 
48 hours of stimulation was correlated with the previous available time point from the time- 
resolved transcriptome analysis, which was 24 hours.  
As can be seen in Figure 16, the gene expression profile is highly correlated with the 
protein pattern from the secretome. The correlation is described by the Pearson correlation 
coefficient R=0.76. Among the secreted proteins, the most upregulated proteins were 
lipocalin 2 (Lcn2), chitinase-3-like protein 1 (Chi3l1), and complement C3 with higher fold 
changes on the protein level, as compared to the gene expression. On the transcriptome 
level, the highest relative increase was detected for Cxcl6, autotoxin (Enpp2) and 
phospholipase 2 group II a (Pla2g2a), all of which demonstrated more prominent relative 
ratios on the gene expression level as compared to the fold changes on the secretome 
level. Overall, higher fold changes of proteins are linked with lower fold changes of the 
respective gene expression, as can be seen from the equation of the trend line y=0.66x-
0.23, where x and y denotes fold change from the secretome and fold change from the 
transcriptome, respectively. 
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Figure 16: S100A1-triggered transcriptomic changes in cardiac fibroblasts are highly 
correlated with the relative changes of the protein secretion. 
Relative gene expression changes after 24 hours are strongly correlated with the fold changes of the 
secreted proteins after 48 hours.  The correlation is described by the Pearson correlation coefficient 
R=0.76. Higher fold changes of secretome are correlated with lower fold changes of transcriptome, 
as also seen in the equation of the trend line y=0.66x-0.23. 
(ACF, S100A1 1μM, for the secretome- 0% FCS, n=3, 48 h stimulation, for the transcriptome- 
0.5%FCS, n=1, 24 h stimulation, y denotes fold change secretome [log2], x denotes fold change 
transcriptome [log2]) 
The correlation of the serial transcriptome and secretome data demonstrates that 
according to the Pearson correlation the profile of secreted proteins after 48 hours is highly 
correlated with the respective gene expression pattern after 24 hours. It is consistent with 
the previously reported correlation analysis between the gene expression and protein 
production within the cell, where the profile of transcriptomic and proteomic fold changes 
are clearly interdependent [198]. However, the increase or decrease of the expression at 
the level of individual genes was not an indication that the secreted protein level will be 
changed to the same extent. Furthermore, it has been demonstrated that the amount of 
produced proteins mainly depends on the translational activity, and some gene increases 
might be silenced with a slowed or arrested further translation [172,199,200]. These results 
once again underline the importance of the verification of the transcriptome data on the 
level of proteins. 
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6.2.3 Biological Functions of Secretome  
Analysis of the serial transcriptome from cardiac fibroblasts upon stimulation with S100A1 
revealed a prominent upregulation of the inflammatory gene pattern with reduced stress 
fiber and extracellular matrix gene activity. In order to validate the transcriptional changes 
and define specific biological functions of the secreted protein profile, a functional 
enrichment analysis of the secretome was performed. 
At first, all relative fold changes of the secreted proteins were sorted with 1D annotation 
enrichment. For the annotation, category identifiers of biological process, molecular 
function, and keywords from UniProt [171] were used. The enrichment was depicted as a 
position score, which shows the center of distribution for the values of the particular 
category in relation to the distribution of all values. Categories closer to -1 stand for the 
enrichment among proteins with low relative ratios, whereas shift towards 1 indicates the 
enrichment among proteins with high relative ratios (for the details see section 5.2.6.3 
Statistical Analysis and Biological Classification ). 
In Figure 17 the 1D enrichment analysis of the most upregulated and downregulated 
protein categories is summarized. The upregulated protein categories comprised 
numerously more entities with higher position scores. Chemotaxis, chemokine receptor 
binding, and chemokine activity were the most prominently increased categories. At the 
same time the most downregulated categories were collagens and extracellular matrix part 
(the detailed analysis and list of proteins per category see Supplementary table 2, 
Supplementary table 3, Supplementary table 4). These data support results from 
transcriptome analysis, suggesting that S100A1 elicits distinct activation of cardiac 
fibroblasts from the well-known myofibroblast phenotype that is characterized by the 
increased extracellular matrix protein secretion [106,201].  
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Figure 17: S100A1 evokes upregulation of inflammatory protein secretion and downregulation 
of extracellular matrix components in cardiac fibroblasts. 
All secreted proteins were clustered together with a 1D annotation enrichment according to their 
relative ratios. The most downregulated categories are collagen and extracellular matrix part. The 
most upregulated functions are chemotaxis, chemokine receptor binding, and chemokine activity. 
Enrichment per category is indicated as a position score, where the center of values of particular 
category is depicted in relation to the center of values from the rest of members, which are included 
in the calculation. 
(ACF, n=3, S100A1 1μM, 48 h stimulation, 0% FCS) 
In order to cluster upregulated proteins into categories according to their biological function 
Fisher’s exact test was applied. Similar to 1D annotation enrichment analysis, labels from 
UniProt, which comprised biological process, molecular function and keywords, were 
applied. In 1D annotation enrichment all ratios are taken into account, thus also a small 
increase in protein secretion contributes to the overall enrichment of the particular 
functional category. In contrast to 1D annotation enrichment, in the Fisher’s exact test the 
threshold value for the upregulation of each protein must be introduced. Within this group 
no further ranking of the proteins according to their fold changes is applied. As a threshold 
level a 4-fold increase was used. Biological functions were ranked according to the 
enrichment factor, which indicates the number of proteins from the particular category with 
more than 4-fold upregulation versus the total number of detected proteins from the same 
category (for the formula of the calculation see section 5.2.6.3 Statistical Analysis and 
Biological Classification ).  
Results of the Fisher’s exact test are shown in Figure 18. All the highest enriched functions 
were related to different aspects of inflammatory reaction. The three top-rated categories 
were chemokine-mediated signaling pathway, chemotaxis, and chemokine activity, which 
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indicates a strong induction of chemoattractant protein secretion. The full analysis of the 
Fisher’s exact test is given in Supplementary table 5. 
 
Figure 18: Functions that are responsible for chemoattraction are the most enriched 
categories among the upregulated proteins in the secretome from cardiac fibroblasts 
stimulated with S100A1. 
Fisher’s exact test of biological functions for more than 4-fold upregulated secreted proteins. The 
most enriched functions are chemokine-mediated signaling pathway, chemotaxis and chemokine 
receptor binding. 
The value of enrichment factor indicates the size of the group of more than 4-fold upregulated 
proteins, which belong to the particular category, normalized with the number of all proteins from the 
same category. 
(ACF, n=3, S100A1 1μM, 48 h stimulation, 0% FCS) 
The highest stimulatory effect of S100A1 is exerted on the inflammatory response, as can 
be seen from the most upregulated biological functions (Figure 18). The proteins that 
define the first 15 most enriched categories from the Fisher’s test are listed in Table 4. 
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Chemoattractants are highlighted in dark blue. They determined the first three most 
enriched functions from the Fisher’s test. It is important to note that these proteins match 
also with the members of the first three most upregulated functions according to the 1D 
annotation enrichment analysis (see Supplementary table 3).  
Table 4: Proteins that determine the enrichment of immune response functions according to 
Fisher’s exact test in the secretome from S100A1 stimulated cardiac fibroblasts.  
In dark blue highlighted proteins corresponds to the three most upregulated biological functions, 
which cover the chemoattraction functions. 
Gene name Protein name 
Fold 
changes 
[log2] 
Gene name Protein name 
Fold 
changes 
[log2] 
Lcn2 Lipocalin-2 7.91 Pf4 Platelet factor 4 3.02 
C3 Complement C3 6.46 Sod2 
Manganese-
superoxide 
dismutase 
2.80 
Ptx3 Pentraxin 3 6.41 Mmp9 
Matrix 
metalloproteinase-
9 
2.74 
Cxcl1 
C-X-C motif 
chemokine 1 
6.00 Cd44 
Phagocytic 
glycoprotein-1 
2.73 
Ccl7 
C-C motif 
chemokine 7 
5.12 Tnfrsf11b Osteoprotegerin 2.67 
Ccl2 
C-C motif 
chemokine 2 
5.05 Rarres2 Chemerin 2.67 
Cxcl6 
C-X-C motif 
chemokine 6 
4.91 Mmp2 
Matrix 
metalloproteinase-
2 
2.49 
C1s 
Complement C1s 
subcomponent 
4.81 Csf1 
Macrophage 
colony-stimulating 
factor 1 
2,45 
Enpp2 Autotaxin 4.81 Cxcl12 
Stromal cell-
derived factor 1 
2.41 
Serping1 
Plasma protease 
C1 inhibitor 
4.22 Spp1 Osteopontin 2.35 
Lbp 
Lipopolysaccharide-
binding protein 
3.78 Mmp10 Stromelysin 2 2.33 
Ccl3 
C-C motif 
chemokine 3 
3.73 C1r 
Complement C1r 
subcomponent 
2.25 
Hp Haptoglobin 3.71 Cxcl3 
C-X-C motif 
chemokine 3 
2.16 
Serpina3n 
Serine protease 
inhibitor A3N 
3.49 Pla2g7 
Phospholipase 
A2, group VII 
2.09 
Dcn Decorin 3.43    
 
The functional enrichment analysis of the secretome indicated a prominent upregulation 
of immune response, in particular, chemoattractant function. It was accompanied by a 
moderately decreased secretion of extracellular matrix structural proteins, thereby 
confirming the results from the serial transcriptome analysis (see section 6.1.2). In the 
following analysis, the effect of stimulation with S100A1 on the absolute amounts of 
proteins was examined. 
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6.2.4 Effect of S100A1 on Absolute Protein Amounts  
Previously described biological functions and significantly upregulated single proteins 
were calculated based on the relative changes of each protein in the supernatant from 
S100A1-stimulated fibroblasts. However, this approach neglects the total amounts of 
proteins. Hence, it is not possible to evaluate whether the S100A1-elicited changes of the 
protein profile and biological functions relevantly impacts the absolute profile of secreted 
proteins and prevailing functions of cardiac fibroblasts. To distinguish, whether the 
detected alterations are minor deviations or notable hallmarks of a new pattern of the 
secretome of cardiac fibroblasts, proteins were sorted and analyzed according to their 
absolute abundance, expressed as an iBAQ value (in log10). It represents the sum of the 
peak intensities of detected peptides from one protein divided by the number of 
theoretically obtainable peptides per respective protein (for detailed information see 
5.2.6.2). 
1D functional enrichment analysis was performed on the sets of iBAQ values obtained 
from control and S100A1-treated samples. S100A1-targeted proteins, which comprised 
the most upregulated biological functions according to relative ratios, were grouped into a 
separate category. According to Fisher’s exact test the most upregulated biological 
functions were immune response categories (Figure 18). Thus, the respective S100A1-
targeted proteins (highlighted in Table 4) were grouped in a separate category and termed 
“Immune response”. It encompasses 29 proteins, such as lipocalin-2, complement C3 and 
pentraxin 3. From the upregulated immune response categories the top three most 
enriched ones were chemoattractant categories. The proteins, which defined this 
upregulation, were grouped in a separate category “Chemoattractant” (10 proteins, 
highlighted in dark blue, in Table 4). Majority of them were CC or CXC chemokines, such 
as CXCL1, CCL2 and CCL7. 
In the control group (Figure 19A) the 1D enrichment analysis from iBAQ values revealed 
the significant enrichment of collagens, which was detected at the region of proteins with 
the highest absolute abundances (position score 0.57). It is in agreement with the basal 
function of cardiac fibroblasts as extracellular matrix maintaining cells [106]. After the 
stimulation with S100A1 the significantly enriched categories comprised S100A1-targeted 
immune response proteins and, particularly, chemoattractants (Figure 19B). Both of these 
categories were enriched among proteins with highest iBAQ values with a position score 
0.65 for the group of S100A1-targeted chemoattractants and 0.53 for the category of 
S100A1-targeted immune response. Full 1D enrichment analysis is included the 
  Results 
55 
  
Supplementary table 6. These data point towards a phenotypic shift of cardiac fibroblasts 
from collagen- to predominantly chemoattractant-secreting cells in response to S100A1. 
 
Figure 19: The most abundantly secreted proteins are changed from collagens in control to 
immune response factors and chemoattractants, in S100A1-treated fibroblasts.  
The histogram of the distribution of absolute amounts of quantified proteins, expressed in iBAQ 
values (in units of log10), in (A) control and (B) S100A1-treated samples. The colored histograms 
depict proteins that were grouped in significantly enriched categories according to the 1D enrichment 
analysis from iBAQ values of all proteins. In control samples (A) the only significantly enriched 
functional category is collagen (blue histogram) with the position score of 0.57. In the S100A1-
stimulated samples (B) the significantly enriched categories comprised S100A1-targeted 
chemoattractants (dark red histogram) and S100A1-targeted immune response proteins (green 
histogram) with a position score of 0.65 and 0.53, respectively. 
Position score indicates the center of iBAQ distribution of the particular category relative to the 
distribution of all iBAQ values. Values closer to 1 indicates enrichment of the category among the 
proteins with the highest iBAQ values, whereas values towards -1 stands for the enrichment closer 
to the lowest iBAQ values. 
 (ACF, n=3, S100A1 1μM, 48 h stimulation, 0% FCS) 
Next, the composition of the supernatant from S100A1 stimulated fibroblasts was 
evaluated. The absolute abundances of secreted proteins from the stimulated sample 
were plotted as the function of their fold changes (Figure 20). Green filled circles depict 
S100A1-targeted proteins that determine the most upregulated concordant biological 
functions according to Fisher’s exact test, namely, immune response functions. Illustrated 
in dark red are proteins that define the three most upregulated categories, which are 
chemokine-mediated signaling pathway, chemotaxis, and chemokine activity according to 
Fisher’s exact test. From the proteins with common biological functions the most abundant 
and the highest upregulated ones are CCL2, CCL7, CXCL1, pentraxin 3 (Ptx3), and 
lipocalin 2 (Lcn2). Additionally, the first three of them are members of the most enriched 
category upon S100A1 stimulation, "chemoattraction". Moreover, lipocalin 2 is also 
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reported to be a potent chemoattractant [187], thereby supporting the assumption that 
chemotaxis stimulation is the main biological function of the secretome from cardiac 
fibroblasts upon exposure to S100A1. 
 
Figure 20: CCL2 is the most abundantly secreted upregulated protein in S100A1-stimulated 
cardiac fibroblasts.  
Absolute amounts (iBAQ [log10]) of each protein in S100A1-stimulated samples against respective 
ratios from the treatment with S100A1 versus controls (in units of log2). CCL2 possesses the highest 
absolute amount from the detected S100A1-targeted immune response proteins. 
Vertical line separates more than 4-fold upregulated proteins. Solid circles represent proteins, which 
define the upregulation of immune response function, as determined by the Fisher’s exact test. Dark 
red triangles depict proteins, which determine the enrichment of predominantly upregulated 
chemoattraction function. 
(ACF, n=3, S100A1 1μM, 48 h stimulation, 0% FCS) 
Of all S100A1-targeted immune response proteins, CCL2 was determined to be the most 
abundant one. Evaluation of the iBAQ values for all detected proteins indicated that CCL2 
was among the most secreted proteins from the whole secretome. The only protein that 
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had a higher iBAQ value than CCL2 was biglycane (Bgn), which was slightly 
downregulated upon the stimulation with S100A1.  
The analysis of the absolute abundances of the proteins in the supernatant revealed that 
the secretome of the cardiac fibroblasts upon S100A1 stimulation was shifted towards an 
inflammation governing pattern. Detailed examination of the upregulated proteins 
indicated chemoattractant CCL2 [202] as the most abundantly secreted protein.  
6.2.5 Comparison of Serum Starvation Conditions for Secretome Analysis 
For the transcriptome experiment, cardiac fibroblasts were starved and stimulated in 
DMEM containing 0.5% FCS. For the mass spectrometry analysis, the external protein 
content in the supernatant had to be reduced to a minimum.  Therefore, samples for the 
mass spectrometry based analysis were prepared in DMEM containing no FCS. To 
examine the effect of FCS on the secreted protein profile, the detectable protein 
composition was tested in the cell supernatant from DMEM with 0% or 0.5% FCS 
supplementation with or without additional exposure to S100A1.  
The pattern of proteins after gel electrophoresis from the 0.5% FCS group showed a clear 
accumulation of the serum at the region of 60 kDa, indicating a strong contamination with 
serum albumin (Figure 21A). In the 0.5% FCS group the accumulated serum proteins 
would mask the proteins produced by cardiac fibroblasts, therefore this part of the gel was 
excluded from further mass spectrometry analysis. The protein lane from 0% FCS group, 
on the contrary, was subjected to the LC MS/MS in full length.  
In the next step, the number of detectable extracellular proteins was compared between 
0% and 0.5% FCS groups (Figure 21B). As expected, the 0% FCS treated sample 
contained more proteins than the 0.5% group. 363 and 292 proteins were identified in the 
0% and 0.5% FCS group, respectively. 251 of them were detected in both groups.  
In order to evaluate a possible impact of serum starvation conditions on the protein 
production and secretion, the absolute amounts of each protein from both groups were 
correlated using Pearson correlation coefficient. The absolute protein amounts were 
calculated as an iBAQ (intensity based absolute quantification) value. As shown in the 
Figure 21C, iBAQ values for proteins from 0% and 0.5% FCS group are strongly 
correlated, as described by a Pearson correlation coefficient of R=0.72.  
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Figure 21: Cardiac fibroblast treatment with 0.5% FCS in comparison with 0% FCS leads to 
less proteins detected in the supernatant by mass spectrometry without affecting their 
absolute amount. 
(A) Proteins were separated with a gel electrophoresis and stained with Coomassie blue.  Samples 
with 0.5% FCS treatment showed accumulation of calf serum proteins with the maximum at around 
60 kDa. For the 0.5% FCS group this part of the gel was excluded from the further analysis.  
(B) Proteins were detected by LC MS/MS. The count of proteins in 0% FCS and 0.5% FCS treated 
samples were compared with a BioVenn, a web application for the comparison and visualization of 
biological lists. More proteins was detected in the 0% FCS treated sample. 
(C) Absolute amount of each protein was expressed as iBAQ. The iBAQ values were correlated 
between the 0% and 0.5% FCS treated groups. 0% versus 0.5% FCS treatment had no substantial 
effect on the secreted protein amount, since iBAQ values from both groups were strongly lineary 
correlated (Pearson correlation coefficient R=0.72). 
(ACF, n=1, S100A1 1μM, 48 h stimulation) 
In conclusion, the presence or absence of serum during the stimulation period had no 
major effect on the amounts of detectable secreted proteins; however, due to the serum 
protein accumulation at the region of around 60 kDa this part of the gel could not be used 
for the secreted protein detection with mass spectrometry, resulting in lower number of 
identified proteins.  
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6.3 CCL2 Expression and Secretion by Cardiac Fibroblasts upon 
Stimulation with S100A1  
According to the transcriptome and secretome data, the most upregulated biological 
function in response to S100A1 was chemokine activity. Analysis of single proteins from 
the secretome revealed that CCL2 is the most abundantly secreted chemokine. Therefore, 
the molecular mechanisms underlying increased CCL2 expression and secretion in 
S100A1-stimulated cardiac fibroblasts were further investigated. 
6.3.1 Verification of S100A1-Triggered Upregulation of CCL2  
Since the gene microarray-based approach possesses a high background noise, the 
investigation of single gene expression pattern requires qPCR [170,203]. Due to the limited 
sensitivity of the unlabeled mass spectrometry-based data acquisition [186], for  the 
examination of time-dependent secretion pattern of individual proteins an ELISA assay is 
required. Therefore, CCL2 gene expression and protein secretion were verified and 
investigated by qPCR and ELISA, respectively.   
In order to validate CCL2 gene expression with qPCR, cardiac fibroblasts were stimulated 
with S100A1 for 24 hours. CCL2 gene expression was significantly upregulated, showing 
a 10 fold increase over control (Figure 22A). The secreted protein was verified by treating 
cardiac fibroblasts with S100A1 for 48 hours. Subsequently the conditioned medium was 
subjected to ELISA analysis (Figure 22B). The treatment with S100A1 led to a substantial 
increase of CCL2 amount. In the control samples approximately 1.5 ng/mL of CCL2 was 
detected, whereas in the supernatant from stimulated cardiac fibroblasts the amount of 
CCL2 was increased to 27 ng/mL.  
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Figure 22: S100A1 stimulation of cardiac fibroblasts induces a robust upregulation of CCL2 
gene expression and protein secretion.  
(A) The verification of CCL2 gene expression increase with qPCR. CCL2 expression shows a 
prominent relative upregulation after 24 h treatment with S100A1. (n=5) 
(B) ELISA verification of the upregulated CCL2 protein secretion upon treatment with S100A1 for 48 
h. Stimulated samples contained high absolute amount of CCL2 protein, resulting in a prominent 
increase over control. (n=4) 
(ACF, S100A1 1μM, 0% FCS **p<0.01 vs. control)  
To examine the expression time course of CCL2, cardiac fibroblasts were stimulated with 
S100A1 for 4, 8, 12, 24 and 48 hours. In the data, kindly provided by Dr. Martin Busch, the 
expression increase of CCL2 mRNA started already at 4 hours (Figure 23).  
 
Figure 23: S100A1 induces an early upregulation of CCL2 gene expression. 
Cardiac fibroblasts were incubated with S100A1 for 4, 8, 12, 24 and 48 hours. qPCR measurement 
indicated an increase of CCL2 mRNA already after 4 hours of stimulation. 
(ACF, n=2, S100A1 1μM, 0% FCS) 
Data and figure courtesy of Dr. Martin Busch. 
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The ELISA-based protein measurement indicated a very early upregulation of CCL2 at the 
secreted protein level (Figure 24A). The supernatant from S100A1-stimulated cardiac 
fibroblasts already after 4 hours contained 1.9 ng/mL of CCL2. After 48 hours the amount 
increased to 26 ng/mL. For comparison, control samples at 4 hour time point contained 
only 0.07 ng/mL CCL2, which increased to 2.3 ng/mL at 48 hours. Measuring CCL2 mRNA 
expression in the corresponding experiment, CCL2 was increased over control 23-fold and 
21-fold at the 4 hour and 48 hour time points, respectively (Figure 24B). 
 
 
Figure 24: S100A1 evokes an early and stable upregulation of CCL2 protein secretion and 
mRNA expression.  
Cardiac fibroblasts were stimulated with S100A1 for 4, 8, 12, 24, and 48 hours.  
(A) ELISA of secreted CCL2. The increase of CCL2 protein in the supernatant was detectable already 
after 4 hours and notably accumulated over 48 hours. 
(B) qPCR of CCL2 mRNA expression from the corresponding ELISA experiment. CCL2 was robustly 
increased at all measured time points. 
(ACF, n=1, S100A1 1μM, 0% FCS)  
The ELISA and qPCR experiments indicated a strong and early upregulation of CCL2 
protein secretion and gene expression in cardiac fibroblasts upon stimulation with S100A1. 
The examination of mRNA expression and protein secretion time course showed a 
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prominent induction of CCL2 production already after 4 hours. Further incubation resulted 
in a substantial accumulation of CCL2 in the supernatant at all subsequent time points.  
6.3.2 TLR4-Mediated Increase of CCL2 Expression  
After internalization by cardiac fibroblasts, S100A1 binds to TLR4 [64]. TLR4 is crucially 
involved in the eliciting of inflammatory response after the myocardial infarction [204,205]. 
Activation of TLR4 has been shown to trigger CCL2 production [206]. Therefore, the 
involvement of TLR4 in S100A1-induced increase of CCL2 expression was investigated. 
At first, TLR4 was chemically inhibited by using CLI095, which is also known as a 
resatorvid. It binds specifically to the intracellular domain of TLR4 and interferes with the 
subsequent interaction with TLR4 adaptor proteins that are needed for downstream signal 
transduction [207]. Results of chemical inhibition are shown in Figure 25. 30 minutes pre-
incubation of cardiac fibroblasts with CLI095 completely abolished the S100A1-triggered 
CCL2 upregulation. 
 
Figure 25: Chemical inhibition of TLR4 abolishes S100A1-induced CCL2 upregulation in 
cardiac fibroblasts. 
Cardiac fibroblasts were treated with S100A1 for 24 hours with or without a 30 minute pre-incubation 
with TLR4 chemical inhibitor CLI095. The blockage of TLR4 resulted in a completely abrogated CCL2 
mRNA increase upon the stimulation with S100A1, measured with qPCR. 
(ACF, n=3, S100A1 1μM, CLI095 3 μM, 0% FCS **p<0.01)  
In order to verify the TLR4 pathway-dependent suppression of CCL2 expression, a 
knockdown of TLR4 was established. 48 hours after transfection with TLR4 and scramble 
siRNA, qPCR analysis indicated knockdown to 10% TLR4 expression in comparison to 
scramble controls (Figure 26A). Consequently, cardiac fibroblast stimulation with S100A1 
for 24 hours was performed 48 hours after transfection. After the stimulation with S100A1, 
CCL2 was significantly upregulated in cardiac fibroblasts, which were transfected with the 
scramble siRNA. The stimulation resulted in a 21-fold increase of CCL2 over the untreated 
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scramble control (Figure 26B). TLR4 knockdown suppressed the S100A1-mediated 
upregulation of CCL2.  
 
Figure 26: TLR4 knockdown blocks the increase of CCL2 in S100A1-stimulated cardiac 
fibroblasts. 
(A) Cardiac fibroblasts were transfected with scramble (Scr) and TLR4 siRNA. After 48 h the efficiency 
of knockdown was verified with the qPCR, which showed a 10% rest expression of TLR4.  
(B) 48 h after the transfection cells were stimulated with S100A1 for 24 hours. TLR4 knockdown 
suppressed the upregulation of secreted CCL2 from S100A1-stimulated cardiac fibroblasts.  
(ACF, n=3, S100A1 1μM, Scr and TLR4 siRNA 50 nM, 0% FCS **p<0.01 ***p<0.001) 
Taken together, the data from chemical inhibition and knockdown of TLR4 provide 
evidence for a direct involvement of TLR4 activation in S100A1-triggered increase of CCL2 
expression in cardiac fibroblasts. 
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7 Discussion 
Upon myocardial infarction, S100A1 is released from damaged cardiomyocytes and 
rapidly endocytosed by neighboring cardiac fibroblasts in vivo [64,158,159]. S100A1 
internalization subsequently triggers activation of ERK1/2 and NFκB signaling pathways 
in cardiac fibroblasts, resulting in fundamental gene expression changes of inflammatory 
and fibrotic genes. The aim of this study was to provide a detailed characterization of the 
S100A1-mediated cardiac fibroblast phenotype in order to define its possible biological 
function in vivo. For this purpose time-resolved whole transcriptome and comprehensive 
secretome analyses were performed on S100A1-treated adult rat cardiac fibroblasts in 
vitro. Within the first hours of S100A1 stimulation, cardiac fibroblasts acquired a marked 
chemoattractant phenotype. The most abundantly secreted chemokine was CCL2, a 
cytokine that is reported to be critically involved in the healing cascade after myocardial 
infarction [208]. The initial cellular source of CCL2 after myocardial infarction in vivo is so 
far poorly understood [209]. This study provides first evidence for a rapidly evolving 
chemoattractant phenotype of cardiac fibroblasts upon exposure to extracellular S100A1. 
This indicates that cardiac fibroblasts might actively participate in the initiation of the 
inflammatory response to ischemia/reperfusion injury in vivo. 
7.1 Time-Resolved Transcriptomic Analysis of Cardiac 
Fibroblast Phenotype upon Stimulation with S100A1 
Previous studies on both adult and neonatal cardiac fibroblast cell cultures showed an 
anti-fibrotic and both pro- and anti-inflammatory response upon the stimulation with 
S100A1 [64,210]. Effect on the inflammatory response was demonstrated by the increase 
of pro-inflammatory ICAM1 and anti-inflammatory IL10 expression. Anti-fibrotic effect was 
detected by a prominent downregulation of collagen 1 and αSMA [64,210]. Since the 
downregulation of pro-fibrotic genes contradicts the classical fibroblast activation and 
transformation into myofibroblasts [211], a time-resolved transcriptome analysis was 
performed in order to elucidate the whole gene expression profile of cardiac fibroblasts 
upon their exposure to extracellular S100A1. This approach was chosen because it offers 
a comprehensive and unbiased estimation of all gene expression driven events, 
discriminated by an early or late manifestation. For the evaluation of the complete 
transcriptomic profile over time a principal component analysis was performed. It reduces 
multiple gene expressions of samples to only two dimensions, which represents the 
greatest variances of gene expressions between different samples. Thereby, principal 
component analysis allows the evaluation of the degree by which samples differ from each 
other. 
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S100A1 elicited an early and marked cardiac fibroblast activation. Notably, already after 2 
to 4 hours of stimulation with S100A1, the gene expression profile strongly deviated away 
from the control fibroblasts. The gene expression pattern upon treatment with S100A1 
dynamically changed until the last measured time point at 48 hours. The effect of cell 
culturing conditions on the gene expression changes were measured by the principal 
component analysis of unstimulated samples, which showed only modest changes.  
In order to understand the biological role of the gene expression changes upon S100A1 
stimulation a gene set enrichment analysis (GSEA) was performed. GSEA is a 
computational tool that allows to build a hypothesis about possible biological functions. It 
is based on the clustering of gene expression ratios according to their involvement in 
different biological pathways [169,170]. This approach provides several advantages over 
the conventional focus on the individual most up- or downregulated genes, especially in 
the evaluation of differentially regulated cellular processes. First, the biological function 
may be driven by the majority of regulated genes, which individually do not possess high 
relative changes. Second, the group of the most upregulated genes may include members 
without a concordant biological function. Finally, it may be hard to reproduce the results of 
relative changes of individual genes, since the gene microarrays possess a high 
background noise. GSEA overcomes these limitations by an unbiased functional 
classification that is based on the analysis of all gene expression changes [169,170,203].  
GSEA of S100A1 stimulated cardiac fibroblasts revealed an early and strong upregulation 
of inflammatory biological functions. Already after 1 hour, the chemokine activity was the 
most upregulated function, remaining the most notably increased biological activity at all 
subsequent time points. It is in line with the transcriptome analysis of cardiac fibroblasts 
upon the treatment with S100A8/9, which is another DAMP that is involved in 
cardiovascular pathologies [98]. There the most upregulated function has been reported 
to be chemokine activity [134]. Also other highly upregulated functions upon stimulation 
with S100A1 covered different aspects of inflammatory activity, such as response to tumor 
necrosis factor or neutrophil chemotaxis.  
Besides biological functions, GSEA categories include intracellular signaling pathways, 
which are predicted according to gene expression changes that are reported to be driven 
by the activation of particular signaling cascades. Stimulation with S100A1 led to 
enrichment of categories ERK1/2, NFκB and TLR4 signaling pathway. To TLR4 signaling 
pathway annotated genes with the highest relative expression changes after 24 hours 
were Tnip3, Lbp and Nfkbia. For I-kappaB kinase/NF-kappa B signaling the top three 
genes were ILβ, ILα and Tnfaip3, and for ERK1 and ERK2 cascade- Pla2g2a, CCL3 and 
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Chi3l1 [212]. Activation of these pathways agrees well with previous results about the 
signaling cascades, which are activated by the extracellular S100A1 [64,157,181].  
The downregulated GSEA categories comprised of genes that are responsible for 
cytoskeleton and stress fibers, as well as extracellular matrix formation. This finding 
emphasizes a new type of fibroblast activation that differs from the formation of 
myofibroblasts, which are characterized by an increased αSMA content and extensive 
collagen production [63,64,201]. This observation resembles the response to IL1α and 
cytokine ILβ, which have been reported to also decrease αSMA and collagen production 
[131,213]. In addition, the downregulated categories included also cholesterol biosynthetic 
activity and various mitosis related categories, such as spindle microtubule, condensed 
chromosome kinetochore and chromosome segregation. The suppression of mitotic 
components and cholesterol synthesis, which is a structural cell membrane component 
[214], might indicate an inhibited proliferative activity. At the same time the category 
positive cell proliferation was listed among the upregulated functions. In addition, previous 
studies have demonstrated no impact of extracellular S100A1 on the proliferation rate of 
cardiac fibroblasts [64,179,182].  
7.2 Changes of Cardiac Fibroblast Secretome upon Stimulation 
with S100A1 
The amount of proteins, which are determinants of the biological phenotype, mainly 
depends on the efficiency of translation, therefore the cellular response on mRNA level 
requires confirmation on protein level [215]. Since the most prominently changed biological 
categories from the transcriptome analysis implied production of secreted proteins, such 
as cytokines and collagens, extracellular proteins were of particular interest for this study. 
In order to further investigate the phenotype of S100A1-treated adult cardiac fibroblasts, 
their secretome was analyzed with mass spectrometry.  
Mass spectrometry allows a large-scale investigation of extracellular matrix protein 
secretion upon different stimuli, as well as evaluation of the composition and secretion rate 
of signaling molecules, that ensure the subsequent intercellular communication [216,217]. 
To date, this study provides the first analysis of the complete secretome of cardiac 
fibroblasts upon their exposure to a cardiovascular DAMP. 
7.2.1 Relative Changes in Amounts of Secreted Proteins 
The effect of S100A1 on cardiac fibroblasts was analyzed by calculating relative changes 
of individual proteins and grouping their ratios into clusters according to their biological 
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functions.  Relative changes of individual secreted proteins were evaluated by visualizing 
the p-value against relative ratio in a volcano plot.  
The visualization of the relative changes of individual secreted proteins upon the treatment 
with S100A1 in the volcano plot revealed a strong stimulatory and low suppressive effect. 
The majority of secreted proteins belonged to the upregulated proteins that possessed 
also the most notable relative changes.  
Conventionally, the volcano plot is also used to define the proteins, which are the most 
probable candidates for the cause of the biological effect of stimulation under investigation 
[218,219]. However, the determination of the biological effect via the investigation of 
functions of individual, highest ranked proteins faces several problems. For example, 
highest ranked proteins may have contradictive functions, small relative changes 
collectively may notably impact the biological function, and a small number of experiments 
is linked to reduced power of significance due to biological variance. 
To overcome the limitations of individual protein analysis, biological functions of the 
secretome from S100A1-treated fibroblasts were evaluated by grouping proteins into 
functional categories. Enrichment and significance of each category were calculated with 
1D annotation enrichment and Fisher’s exact test. 1D annotation enrichment employs all 
relative changes, independent of their numerical value. Fisher’s exact test uses relative 
changes above or below a certain threshold, thereby only assessing biological functions 
from the most notably changed proteins.  
1D annotation enrichment analysis revealed a strong activation of proteins with a 
chemokine activity, which was also reflected in the results from transcriptome analysis. 
The most downregulated categories were collagens and extracellular matrix part, however, 
with a mediocre median ratio of downregulation. Since upregulated proteins formed the 
major part of population, Fishers exact test was applied to the group of proteins with at 
least 4-fold increase. The first 15 most upregulated functions comprised various 
inflammatory related categories, from which the most upregulated ones again were 
chemokines and chemotaxis. These findings indicate that the stimulation of cardiac 
fibroblasts with S100A1 induces the chemoattractant function, while simultaneously 
suppressing myofibroblast-related activation. 
7.2.2 Absolute Changes in Amounts of Secreted Proteins 
While the investigation of relative protein changes is useful for the characterization of the 
secretome’s biological function, the relative ratios cannot predict the impact of the global 
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secreted protein profile. If, for example, the protein content in the control sample is close 
to zero, a prominent relative ratio can potentially be derived from a small absolute amount 
of protein in the stimulated sample. 
In order to investigate the impact of S100A1-elicited changes on the cardiac fibroblast 
secretome, proteins were evaluated according to their absolute amounts applying protein 
functional clustering by 1D annotation enrichment analysis. In the control samples, the 
most significantly enriched category was collagen. Upon stimulation with S100A1, the 
most significantly enriched category was chemoattractants, representing the category with 
the highest average absolute amount. In other words, S100A1-treated cardiac fibroblasts 
predominantly secrete chemoattractants, whereas the secretome from control cells is 
dominated by collagens, as assessed by absolute abundances of secreted proteins. This 
suggests that cardiac fibroblasts could execute the surveilling and alarming function in the 
initial inflammatory phase of myocardial infarction by sensing DAMPs and subsequently 
acquiring a pronounced chemoattractant phenotype. 
Since cardiac fibroblasts also produce collagenases MMP2 and MMP9 upon treatment 
with S100A1, it is not possible to specifically attribute the reduced amount of collagens to 
downregulated production or to increased degradation. For the detection with mass 
spectrometry, proteins are cleaved into peptides with trypsin. Identification of detected 
peptides using sequence databases is therefore performed based on a C-terminal tryptic 
cleavage at lysine and arginine residues [220]. If the protein is already extensively digested 
by another enzymes, mass spectrometry analysis might be misleading, because the 
cleavage products are not recognized by the database and, consequently, the level of 
detected collagens is artificially lower. Yet, the downregulation of collagen gene 
expression was also demonstrated on transcriptome level. Together these results indicate 
that reduced synthesis of collagens plays an important role in the decreased amount of 
collagens in the secretome from S100A1-treated cardiac fibroblasts.  
S100A1 triggers the conversion of cardiac fibroblasts into cells that secrete 
chemoattractants in high abundances. In order to extract the proteins, which determine 
the chemoattractant phenotype, they were ranked according to their absolute abundance 
and relative ratios in S100A1-stimulated sample. The highest ranked chemoattractants 
were CCL2, CXCL1 and CCL7, with CCL2 being the most prominently produced one. 
Moreover, in the complete secretome only biglycane was secreted more than CCL2. 
Hence, upon exposure to the S100A1, cardiac fibroblasts extensively secrete the highly 
potent chemoattractant CCL2 [221], which has previously been reported to be involved in 
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the healing cascade after myocardial infarction by attracting inflammatory cells [222] and 
protecting cardiomyocytes from hypoxia-induced injury [223]. 
7.2.3 Limitations of Secretome Analysis 
Secretome analysis enabled the elucidation of S100A1-targeted biological functions and 
highlighted specific proteins that define this phenotype. However, the detected protein 
profile represented accumulated proteins over 48 hours of treatment. Therefore, the 
detected biological functions and the underlying protein profile illustrated the sum of all 
secretory events during a 48 hour time frame, regardless of early or late manifestation.  
Since the secreted proteins are highly diluted in the cell culture supernatant, their 
successful detection by mass spectrometry requires the concentration of the media [224]. 
For this study, a centrifuge filtration device with a pore size of 3 kDa was used, which might 
have led to the loss of small proteins and bioactive peptides. Yet, chemokines, which are 
small cytokines with a molecular size of 8 to 10 kDa [202,221], were detected and 
calculated to be the most abundantly secreted portion of the secretome.  
7.3 Serum Impact on Secretome from Cardiac Fibroblasts 
Since the secretome analysis by mass spectrometry was performed without labeling 
during cell culturing, 0% FCS starvation was chosen in order to reduce the interference of 
serum proteins with the detection of secreted proteins [224]. However, alteration of the 
serum amount may affect the abundance of secreted proteins [186], therefore, secretomes 
from 0% and 0.5% FCS starved cardiac fibroblasts were compared. The highly abundant 
bovine serum albumin in the 0.5% FCS treated samples masked extracellular proteins of 
a comparable molecular weight, therefore this region was excluded from the further 
analysis of the 0.5% FCS group. Consequently, in samples with 0.5% FCS, the number of 
detected proteins was notably smaller, as compared to control samples. Yet, the absolute 
amount of each protein that was detected under both treatment conditions strongly 
correlated between the 0% and 0.5% FCS treated samples. Hence, no relevant impact of 
serum on the abundance of extracellular proteins was observed. 
In this study, transcriptome analysis was performed in the presence of 0.5% FCS, but 
secretome analysis with 0% FCS. Despite the differences in cell treatment, the correlation 
between the transcriptome and secretome was consistent with the previously described 
association between gene expression and protein production. The amount of produced 
protein depends on the efficiency of translation, where one mRNA can be translated into 
up to 1300 proteins per hour [172,215].  Still, the fold changes on transcriptome level are 
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clearly associated with the fold changes on protein level [196,198]. The transcription profile 
changes of S100A1-treated fibroblasts were highly correlated with secretion, however the 
extent of secretion changes was more prominent.  
7.4 Upregulation of CCL2 in Cardiac Fibroblasts upon Treatment 
with S100A1 
In the setting of myocardial infarction, the absence of CCL2 results in delayed infiltration 
of macrophages, defective efferocytosis of injured cardiomyocytes and reduced density of 
myofibroblasts, highlighting the importance of CCL2 in the resolution of tissue injury [208]. 
However, the initial cellular source of CCL2 and the triggering factors of its production after 
myocardial infarction are so far poorly understood.  S100A1 is rapidly released from 
damaged cardiomyocytes and immediately internalized by the neighboring cardiac 
fibroblasts [64,105], thus signaling cardiac injury. In this study, a mass spectrometry-based 
investigation of the secretome from S100A1-stimulated cardiac fibroblasts revealed CCL2 
as the most abundantly produced upregulated protein. A prominent increase of CCL2 in 
cardiac fibroblasts was also confirmed with qPCR on gene expression level and with 
ELISA on protein level. 
Previous studies have demonstrated that internalized S100A1 binds to TLR4 in cardiac 
fibroblasts [64]. TLR4 activation has been reported to be linked to increased CCL2 
production [206,225]. Therefore, the cascade of TLR4 signaling was investigated as a 
potential mechanism of S100A1-triggered upregulation of CCL2 in S100A1-treated cardiac 
fibroblasts. Both chemical inhibition and siRNA mediated knockdown of TLR4 in cardiac 
fibroblasts resulted in a complete abolishment of S100A1-mediated increase of CCL2 
expression. The downstream activation from TLR4 can be driven by two distinct adaptor 
proteins, MyD88 and TRIF [75]. Additional investigations are required in order to elucidate 
which of these signaling pathways are involved in the increased CCL2 production by 
cardiac fibroblasts upon stimulation with S100A1.  
The secretome analysis in this work has highlighted cardiac fibroblasts as a prominent 
source of CCL2 in response to S100A1, which is a cardiomyocyte derived DAMP, released 
upon myocardial infarction. For the investigation of the time frame, which is needed for the 
initiation of CCL2 secretion, ELISA technique was used. ELISA is less specific than mass 
spectrometry, but more sensitive [184,185]. Examination of gene expression and secreted 
protein amount revealed an early and prominent increase of CCL2 already after 4 hours 
with steady relative increase on gene expression levels and prominent accumulation in the 
supernatant on protein level over 48 hours of stimulation. Since the experiment was 
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performed in one biological replicate, further experiments are required for the statistical 
confirmation of the findings. 
Altogether, these results show that CCL2 is rapidly produced by cardiac fibroblast and 
secreted in high amounts upon S100A1 stimulation. Further studies are needed to clarify, 
whether this effect is restricted only to the exposure to S100A1 or if other DAMPs, which 
are released from cardiomyocytes after infarction, can trigger a similar early induction of 
CCL2 production in cardiac fibroblasts. 
7.5 S100A1-Targeted Upregulated Proteins in the Healing of 
Myocardial Infarction  
As has been shown in a previous study, the blockage of extracellular S100A1 after 
ischemia/reperfusion injury results in an increased infarct size and a reduced left 
ventricular ejection fraction [64]. It was hypothesized that the beneficial effect of 
extracellular S100A1 on healing cascade after cardiac injury might be conveyed through 
activated cardiac fibroblasts [64].  
During the current study cardiac fibroblasts have been identified as a potent source of 
chemoattractants upon stimulation with S100A1. The secreted protein profile suggests 
effect on various inflammatory cells. For example, CXCL1 and CXCL6 are classical 
neutrophil chemoattractants [226–228]. Additionally, CXCL1 participates also in the 
recruitment of monocytes by potentiating their arrest [229]. CXCL12 is a potent 
chemoattractant for lymphocytes and monocytes [230]. CCL2 and CCL7 are strong 
monocyte chemoattractants, which participate also in the recruitment of T lymphocytes 
[221,222,231,232].  Further studies should reveal how the influx of inflammatory cells is 
governed by S100A1-stimulated cardiac fibroblasts over the course of myocardial healing 
in vivo. 
Interestingly, these classical chemoattractants are reported to indirectly and directly 
potentiate angiogenesis. During wound healing angiogenesis require controlled 
extracellular matrix proteolysis that activates angiogenic growth factors and facilitates 
endothelial cell migration [233]. Chemoattractant-mediated influx of neutrophils, which 
further secrete proteolytic enzymes, enables initiation of neoangiogenesis [234]. 
Additionally, CXCL1 and CXCL6 induces endothelial cell chemotaxis in vitro and 
neovascularization of rat cornea in vivo [235].  CXCL12 chemoattracts hematopoietic stem 
cells [236]. CCL2 induces migration of endothelial cells and CCL7 stimulates chemotaxis 
of circulating angiogenic cells and angiogenesis in Matrigel plugs, implanted in mice 
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[237,238]. These findings suggest facilitation of restorative angiogenesis by S100A1-
induced proteins through promoting inflammatory and endothelial cell migration. 
Several upregulated proteins upon stimulation with S100A1 have been reported to be 
involved in the cardiomyocyte survival after ischemic injury. For example, pentraxin 3, 
CXCL12 and CCL2 have been shown to protect cardiomyocytes from ischemic injury 
[190,223,239], whereas Pla2g2a is known to mark ischemically damaged cardiomyocytes 
by binding to the flip-flopped components of the cell membrane and thereby facilitating 
their clearance [240]. These findings point out a potential indirect S100A1 involvement in 
the preservation of viable cardiomyocytes during the ischemia/reperfusion stress. 
To sum up, S100A1 mediates an intense activation of cardiac fibroblasts, triggering 
massive production and secretion of chemoattractants, which are reported to recruit 
various inflammatory and endothelial cells. This activation might accelerate resolution of 
the infarction by timely clearance of cellular debris and promoted angiogenesis. In addition, 
S100A1-stimulated cardiac fibroblasts secrete also cardiomyocyte-protecting proteins 
together with marker for terminally injured cells. Such composition might selectively 
preserve viable cardiomyocytes, while simultaneously potentiating clearance of lethally 
damaged cells. Further investigation should clarify whether these effects are responsible 
for the protective activity of extracellular S100A1 on the size of infarction and heart function 
after the ischemia/reperfusion injury in vivo. 
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8 Conclusion and Outlook 
Myocardial infarction elicits a strong inflammatory response that ensures the resolution of 
injured tissues and initiates subsequent replacement of the lost area with a durable scar. 
DAMPs are the principal signaling molecules, which evoke the inflammatory cascade, 
however, the underlying cellular mechanism of how inflammatory cells are alarmed and 
guided to the injury is largely unknown. This study elucidated the detailed effect of S100A1, 
which is a cardiomyocyte derived DAMP, on cardiac fibroblast secretory profile. A potential 
initial signaling mechanism for the attraction of inflammatory cells upon myocardial injury 
was discovered. 
Upon exposure to S100A1 cardiac fibroblasts acquire a pronounced inflammatory 
phenotype, characterized by expressed gene and secreted protein profile. Unlike the 
transformation into myofibroblasts, this type of fibroblast activation is a rapid process, 
which take effect already in the first hours of stimulation. Besides increased inflammatory 
protein secretion it is also characterized by decreased extracellular matrix production. 
Such activation pattern suggests the importance of fibroblasts not only in the phase of scar 
formation but also in the initiation of the inflammatory stage after the myocardial infarction. 
In the presence of extracellular S100A1 the most abundantly secreted upregulated 
proteins in cardiac fibroblasts are chemoattractants, and among them- CCL2, which is a 
crucial chemokine for the inflammatory monocyte recruitment.  
The findings from this work have raised several questions, which should be addressed in 
further studies: 
1) Do other cardiovascular DAMPs, which are released along with S100A1, elicit 
similar activation of an early inflammatory protein profile in cardiac fibroblasts? 
2) Is the inflammatory phenotype of cardiac fibroblasts reversible after the withdrawal 
of stimuli? 
3) Is the inflammatory phenotype the predominant early activation form of cardiac 
fibroblasts in the in vivo setting of myocardial infarction? 
4)  What is the contribution of cardiac fibroblasts to the initiation of inflammatory 
response upon myocardial infarction in vivo?  
Currently, scar formation is the best described function of cardiac fibroblast upon 
myocardial infarction, where fibroblasts transform into secretory active myofibroblasts. 
This study demonstrates an early and strong transformation of cardiac fibroblasts into 
chemoattractant phenotype upon exposure to S100A1, which is released from injured 
cardiomyocytes. Accordingly, it provides the first evidence that the initial function of cardiac 
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fibroblasts upon myocardial infarction might be sensing the tissue injury and triggering the 
influx of debris-resolving inflammatory cells. 
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10 Appendix 
Supplementary table 1: Up- and downregulated proteins from the volcano plot of the 
secretome from the Figure 15. 
In the table are listed proteins with at least 2-fold up- or downregulation. 
No. Gene symbol Protein name 
Fold 
change 
[log2] 
p-value       
[-log10] 
iBAQ in 
control 
[log10] 
iBAQ in 
S100A1 
[log10] 
1 Lcn2 Lipocalin 2  7.91 1.63 6.66 8.47 
2 Chi3l1 Chitinase-3-like protein 1  6.91 1.58 7.35 9.02 
3 C3 Complement C3 6.46 2.16 6.58 7.94 
4 Ptx3 Pentraxin 3  6.41 1.79 7.42 8.82 
5 Cxcl1 C-X-C motif chemokine 1 6.00 1.37 6.41 8.55 
6 Clu Clusterin 5.60 2.35 6.96 8.64 
7 Pla2g2a 
Phospholipase A2, membrane 
associated 
5.14 4.09 4.89 7.05 
8 Ccl7 C-C motif chemokine 7 5.12 1.15 7.62 8.88 
9 Ccl2 C-C motif chemokine 2 5.05 1.76 8.12 9.21 
10 Cxcl6 C-X-C motif chemokine 6 4.91 2.09 6.48 8.29 
11 C1s Complement C1s 4.81 1.06 6.29 7.45 
12 Enpp2 Autotaxin 4.81 1.30 7.09 7.90 
13 Mgp Matrix Gla protein 4.48 1.39 7.28 8.59 
14 Igfbp3 
Insulin-like growth factor-binding 
protein 3 
4.45 2.01 7.96 8.94 
15 Serping1 Plasma protease C1 inhibitor 4.22 1.92 7.97 8.64 
16 C1s Complement C1s subcomponent 3.99 1.37 8.49 8.93 
17 Lbp 
Lipopolysaccharide-binding 
protein 
3.78 2.26 7.45 8.21 
18 Hp Haptoglobin 3.71 0.82 6.50 8.14 
19 Serpina3n Serine protease inhibitor A3N 3.49 1.45 7.17 7.99 
20 Dcn Decorin 3.43 1.10 8.01 9.01 
21 Mmp14 Matrix metalloproteinase-14 2.82 1.08 6.55 7.37 
22 Sod2 
Manganese-superoxide 
dismutase 
2.80 1.94 7.43 8.08 
23 Fst Follistatin 2.76 0.81 6.31 6.97 
24 Atp5b ATP synthase, subunit beta 2.76 1.43 6.25 6.95 
25 Mmp9 Matrix metalloproteinase-9 2.74 1.37 5.30 6.58 
26 Tnfrsf11b Osteoprotegerin 2.67 1.63 6.79 7.40 
27 Rarres2 Chemerin 2.67 1.89 7.37 8.30 
28 Mmp2 Matrix metalloproteinase-2 2.49 1.68 8.42 8.92 
29 Csf1 
Macrophage colony-stimulating 
factor 1 
2.45 1.03 6.77 7.40 
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30 Ltbp1 
Latent-transforming growth factor 
beta-binding protein 1 
2.38 0.60 5.57 6.32 
31 Lgals3bp Galectin-3-binding protein 2.31 1.96 7.97 8.39 
32 C1r Complement C1r subcomponent 2.25 2.37 8.57 8.83 
33 Cp Ceruloplasmin 2.18 1.22 6.07 6.58 
34 Pla2g7 Phospholipase A2, group VII 2.09 2.48 6.50 7.03 
35 Aprt 
Adenine 
phosphoribosyltransferase 
2.07 0.92 5.91 6.52 
36 Pgk1 Phosphoglycerate kinase 1 2.00 1.13 6.49 6.98 
37 Hist1h2bl Histone H2B 1.97 0.48 7.69 8.00 
38 Cfl1 Cofilin-1 1.82 1.91 7.46 7.79 
39 Thbs2 Thrombospondin-2 1.78 1.69 7.36 7.72 
40 Gda Guanine deaminase 1.76 1.04 6.50 7.01 
41 Mdh2 Malate dehydrogenase 1.76 2.89 7.30 7.80 
42 Abi3bp Protein Abi3bp 1.70 2.20 6.92 7.45 
43 Ran GTP-binding nuclear protein Ran 1.62 0.64 6.27 6.68 
44 Mmp11 Stromelysin-3 1.59 1.20 7.24 7.55 
45 Sod1 Superoxide dismutase [Cu-Zn] 1.57 1.20 7.38 7.77 
46 Epdr1 
Mammalian ependymin-related 
protein 1 
1.55 0.51 7.44 7.39 
47 Akr1b1 Aldose reductase 1.52 0.68 7.01 7.23 
48 Eef1a1 Elongation factor 1-alpha 1 1.52 1.91 7.61 7.92 
49 Pdia6 Protein disulfide-isomerase A6 1.49 1.25 6.82 7.15 
50 C4 Complement C4 1.48 0.83 6.83 7.06 
51 Capg Macrophage-capping protein 1.47 1.39 6.41 6.77 
52 Gstm2 Glutathione S-transferase Mu 2 1.43 1.70 6.17 6.48 
53 Ctsh Pro-cathepsin H 1.43 1.50 7.43 7.73 
54 Pdia3 Protein disulfide-isomerase A3 1.40 1.26 7.49 7.77 
55 Eno1 Alpha-enolase 1.39 1.28 7.71 8.05 
56 Rpl12 60S ribosomal protein L12 1.37 0.89 7.01 7.28 
57 H3f3c Histone H3 1.33 0.43 7.27 7.50 
58 Calu Calumenin 1.33 0.79 7.48 7.64 
59 Sdf4 45 kDa calcium-binding protein 1.33 0.99 6.58 7.01 
60 Timp1 Metalloproteinase inhibitor 1 1.32 1.18 8.26 8.59 
61 Ppib 
Peptidyl-prolyl cis-trans isomerase 
B 
1.30 1.15 8.32 8.49 
62 Prdx2 Peroxiredoxin-2 1.30 1.56 7.20 7.49 
63 Hspa5 78 kDa glucose-regulated protein 1.29 1.30 7.23 7.54 
64 Fabp5 
Fatty acid-binding protein, 
epidermal 
1.28 0.58 7.06 7.21 
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65 Ppia 
Peptidyl-prolyl cis-trans isomerase 
A 
1.26 1.89 7.94 8.20 
66 Cap1 
Adenylyl cyclase-associated 
protein 1 
1.21 0.88 6.04 6.38 
67 Prelp Prolargin 1.20 0.61 6.70 6.79 
68 Serpinb6 Protein Serpinb6 1.20 2.30 6.44 6.76 
69 B2m Beta-2-microglobulin 1.18 2.78 8.65 8.83 
70 Ctsb Cathepsin B 1.18 2.33 8.39 8.62 
71 Gaa Lysosomal alpha-glucosidase 1.18 1.40 6.31 6.49 
72 Eef2 Elongation factor 2 1.17 1.24 6.83 7.04 
73 Gdi2 
Rab GDP dissociation inhibitor 
beta 
1.15 1.61 7.13 7.36 
74 Sdcbp Syntenin-1 1.14 1.57 7.22 7.50 
75 Hsp90aa1 Heat shock protein HSP 90-alpha 1.14 1.09 6.48 6.47 
76 Postn Periostin 1.12 1.73 8.96 9.16 
77 Ldha L-lactate dehydrogenase 1.11 3.30 8.06 8.26 
78 Kpnb1 Importin subunit beta-1 1.11 0.82 5.78 6.09 
79 Emilin1 Elastin microfibril interfacer 1 1.10 0.89 6.74 7.13 
80 Aldoa Fructose-bisphosphate aldolase A 1.08 1.00 7.79 8.12 
81 Got1 
Aspartate aminotransferase, 
cytoplasmic 
1.08 0.56 6.35 6.65 
82 Btd Biotinidase 1.06 0.79 6.16 6.32 
83 Dpysl2 
Dihydropyrimidinase-related 
protein 2 
1.05 1.01 6.11 6.39 
84 Actg1 Actin, cytoplasmic 2 1.05 1.60 8.83 9.00 
85 Wdr1 WD repeat-containing protein 1 1.04 0.61 6.66 6.76 
86 Nme2 Nucleoside diphosphate kinase B 1.02 0.96 8.15 8.32 
87 Csrp1 
Cysteine and glycine-rich protein 
1 
1.01 1.00 6.50 6.77 
88 Sod3 
Extracellular superoxide 
dismutase [Cu-Zn] 
1.01 2.24 8.51 8.70 
89 Col3a1 Collagen, type III, alpha 1 -1.01 1.70 8.75 8.27 
90 Islr 
Immunoglobulin superfamily 
containing leucine-rich repeat 
protein 
-1.02 2.23 7.57 7.04 
91 Loxl3 Lysyl oxidase-like 3 -1.04 1.13 6.18 5.71 
92 LOC680322 Histone H2A -1.12 0.17 7.54 7.80 
93 Qsox1 Sulfhydryl oxidase 1 -1.14 0.55 7.21 6.90 
94 Gdf6 Growth/differentiation factor 6 -1.15 2.08 6.91 6.40 
95 Olfml1 Olfactomedin-like protein 1 -1.19 2.14 7.13 6.54 
96 Tgfb3 Transforming growth factor beta-3 -1.22 2.55 7.14 6.69 
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97 C1qb 
Complement C1q subcomponent 
subunit B 
-1.22 0.61 6.98 6.67 
98 Tpp1 Tripeptidyl-peptidase 1 -1.23 0.47 7.80 7.56 
99 Hspg2 Protein Hspg2 -1.23 1.32 8.36 7.91 
100 Vegfc 
Vascular endothelial growth factor 
C 
-1.30 2.23 7.02 6.52 
101 Ogn Osteoglycin -1.45 3.03 8.08 7.39 
102 Loxl2 Lysyl oxidase homolog 2 -1.56 1.11 7.33 6.70 
103 Gpc6 Protein Gpc6 -1.59 0.96 6.88 6.24 
104 Fstl3 Follistatin-related protein 3 -1.72 0.59 7.12 6.50 
105 Clec3b 
C-type lectin domain family 3, 
member B  
-1.80 2.20 8.22 7.49 
106 Col8a1 Collagen, type VIII, alpha 1  -1.94 2.32 7.79 7.26 
107 Eln Elastin -2.42 1.00 8.29 7.18 
 
Supplementary table 2: 1D annotation enrichment analysis of the ratios of proteins [log2] from 
the secretome (see section 6.2.3 Biological Functions of Secretome ). 
Size- the number of proteins, forming the particular category; position score- the center of iBAQ value 
distribution of the particular category relative to the distribution of all iBAQ values; adjusted p-value- 
p-value for the enrichment of category with Benjamini-Hochberg FDR 2%; mean- mean of the fold-
changes of proteins from the particular category; median- median of the fold-changes of proteins from 
the particular category. 
Category Size Score 
Adjusted        
p-value 
Mean Median 
Collagen 15 -0.70 4.65E-06 -0.59 -0.49 
Extracellular matrix 
part 
52 -0.49 4.97E-06 -0.17 -0.32 
Cytokine 14 0.62 0.00296 2.77 2.56 
G-protein-coupled 
receptor binding 
11 0.71 0.00652 3.32 3.02 
Chemokine activity 8 0.88 0.01437 3.62 3.37 
Chemokine receptor 
binding 
8 0.88 0.00718 3.62 3.37 
Chemotaxis 10 0.92 4.70E-05 4.29 4.86 
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Supplementary table 3: Proteins from the upregulated categories according to the 1D 
annotation enrichment analysis of  median ratios of proteins [log2] from secretome. 
Gene 
symbol 
Fold 
change 
[log2] 
Category 
Chemotaxis 
Chemokine 
receptor 
binding 
Chemokine 
activity 
G-protein-coupled 
receptor binding 
Cytokine 
C3 6.46 x   x  
Calm1 0.57    x  
Ccl2 5.05 x x x x x 
Ccl3 3.73 x x x x x 
Ccl7 5.12 x    x 
Csf1 2.45     x 
Cx3cl1 1.67 x x x x x 
Cxcl1 6.00 x x x x x 
Cxcl12 2.41  x x x  
Cxcl3 2.16 x x x x x 
Cxcl6 4.91 x x x x x 
Enpp2 4.81 x     
Flna 0.56    x  
Gdf6 -1.15     x 
Gpi 0.78     x 
Grn 0.01     x 
Pf4 3.02 x x x x x 
Spp1 2.35     x 
Tnfrsf11b 2.67     x 
 
Supplementary table 4: Proteins from downregulated categories according to the 1D 
annotation enrichment analysis of median ratios of proteins [log2] from secretome. 
Gene 
symbol 
Fold 
change 
[log2] 
Category 
Collagen 
Extracellular 
matrix part 
Col11a1 -0.68 x x 
Col12a1 -0.17 x  
Col14a1 -0.09 x  
Col15a1 -0.54 x x 
Col1a1 -0.93 x x 
Col1a2 -0.98 x x 
Col3a1 -1.01 x x 
Col4a1 -0.24 x x 
Col4a2 -0.35 x x 
Col5a1 -0.83 x x 
Col5a2 -0.49 x x 
Col6a1 -0.08 x  
Col6a2 -0.13 x x 
Col6a3 -0.36 x  
Col8a1 -1.94 x x 
Agrn 0.11  x 
Ang 0.34  x 
Anxa2 0.07  x 
Bmp1 -0.73  x 
C1qa -1.10  x 
C1qb -1.22  x 
C1qc -0.54  x 
C1qtnf5 -0.26  x 
Ccdc80 0.03  x 
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Cst3 0.10  x 
Dag1 -0.54  x 
Dcn 3.43  x 
Eln -2.42  x 
Emilin1 1.10  x 
Fbln1 0.39  x 
Fbln5 -0.58  x 
Fbn1 -0.42  x 
Fn1 -0.02  x 
Hspg2 -1.23  x 
Itgb1 0.05  x 
Lama2 -0.39  x 
Lama4 0.10  x 
Lama5 -0.71  x 
Lamb1 0.04  x 
Lamb2 0.11  x 
Lamc1 -0.02  x 
Lox 0.74  x 
Loxl1 -0.47  x 
Loxl2 -1.56  x 
Ltbp1 2.38  x 
Lum 0.72  x 
Mfap5 -0.42  x 
Nid1 -0.29  x 
Nid2 0.31  x 
Plod1 0.24  x 
Serpinf1 -0.39  x 
Sparc -0.88  x 
Tgfb2 -0.66  x 
Thbs2 1.78  x 
Timp1 1.32  x 
Timp2 -0.02  x 
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Supplementary table 5: Top 15 of the most enriched categories according to the Fisher’s exact 
test of proteins with more than 4-fold upregulation from secretome. 
Total size- the number of all proteins; selection size- the number of proteins with at least 4-fold 
upregulation; category size- the number of all proteins, which form the particular category; 
intersection size- the number of proteins with at least 4-fold upregulation from the particular category; 
enrichment factor- the size of the group of at least 4-fold upregulated proteins from the particular 
category, normalized with the count of all proteins from the same category; adjusted p-value- p-value 
for the enrichment of category with Benjamini-Hochberg FDR 2%. 
Category  
Total 
size 
Selection 
size 
Category 
size 
Intersection 
size 
Enrichment 
factor 
Adjusted    
p-value 
Chemokine-mediated 
signaling pathway 
380 52 6 6 7.31 0.00061 
Chemotaxis 380 52 10 9 6.58 4.39E-05 
Chemokine activity 380 52 8 7 6.39 0.00198 
Chemokine receptor 
binding 
380 52 8 7 6.39 0.00149 
Cytokine 380 52 14 10 5.22 8.87E-05 
G-protein-coupled 
receptor binding 
380 52 12 8 4.87 0.00609 
Cell chemotaxis 380 52 15 10 4.87 0.00038 
Positive regulation of 
leukocyte chemotaxis 
380 52 17 11 4.73 0.00024 
Positive regulation of 
leukocyte migration 
380 52 19 12 4.62 0.00012 
Response to 
lipopolysaccharide 
380 52 23 14 4.45 3.27E-05 
Inflammatory response 380 52 25 15 4.38 2.08E-05 
Response to molecule of 
bacterial origin 
380 52 25 14 4.09 8.89E-05 
Immune response 380 52 32 16 3.65 8.92E-05 
Defense response 380 52 41 20 3.56 1.68E-05 
Positive regulation of 
immune system process 
380 52 37 18 3.56 3.51E-05 
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Supplementary table 6: 1D annotation enrichment analysis, calculated from absolute amounts 
of proteins, expressed in iBAQ values [log10], in secretome of control and S100A1-treated 
samples.  
Size- the number of proteins, which form the particular category; position score- the center of iBAQ 
value distribution of the particular category relative to the distribution of all iBAQ values; adjusted p-
value- p-value for the enrichment of category with Benjamini-Hochberg FDR 2%; mean- the mean of 
the iBAQ values of proteins from the particular category; median- the median of the iBAQ values of 
proteins from the particular category. 
Control 
Category Size Score 
Adjusted   
p-value 
Mean Median 
Collagen 15 0.57 0.00019 7.94 7.99 
      
      
S100A1 
Category Size Score 
Adjusted   
p-value 
Mean Median 
Immune 
response 
30 0.53 1.77E-06 7.95 8.03 
Chemoattractant 10 0.65 0.00047 8.13 7.92 
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Supplementary table 7: 2-fold up- or downregulated genes upon stimulation with S100A1 from 
the transcriptome analysis after 48 hours. 
Gene 
symbol 
Fold 
change 
[log2] 
Gene symbol 
Fold 
change 
[log2] 
Gene symbol 
Fold 
change 
[log2] 
Cxcl6 8.15 Serping1 2.58 Flrt2 2.03 
Enpp2 7.71 Duox1 2.58 Ecscr 2.03 
Pla2g2a 6.94 Chrm2 2.57 Pdgfra 2.03 
Lcn2 6.79 Ccl7 2.55 Slc43a3 2.02 
Chi3l1 5.82 Enpep 2.54 Plek 2.02 
Cfb 5.71 Cxcl2 2.54 Rnd1 2.02 
Sfrp2 5.33 Thbs2 2.53 Cyp7b1 2.00 
Slpi 4.92 LOC685067 2.52 C1s 1.99 
C3 4.90 Irg1 2.50 Il1rn 1.99 
Mmp9 4.83 Bst1 2.49 Il2rg 1.99 
Cxcl1 4.77 Isyna1 2.48 Dcn 1.98 
Vcam1 4.39 Tnip3 2.47 Mgst2 1.98 
Naaa 4.31 C4b 2.46 Ccl9 1.98 
Ccl3 4.23 Ch25h 2.46 Cldn15 1.97 
Hp 4.18 Cxadr 2.45 Cx3cl1 1.97 
Clu 4.13 Parm1 2.43 Socs3 1.97 
Sod2 4.06 Trem1 2.41 Slamf6 1.97 
Nos2 3.71 Tnip1 2.38 Cd302 1.96 
Lrrn4 3.67 Acvr1b 2.36 Adora2a 1.96 
Il1b 3.52 Galnt14 2.35 Htr2a 1.95 
Selp 3.48 Tlr2 2.35 Lcp1 1.95 
Ccl12 3.42 RGD1560281 2.35 Slc6a12 1.94 
Emr1 3.38 Serpina3n 2.35 Aldh1a2 1.94 
Igfbp3 3.36 Ugcg 2.35 Kif26b 1.93 
Opn3 3.26 Grem2 2.34 Csf2rb 1.93 
Rac2 3.22 Steap4 2.34 Tnfaip3 1.93 
Lbp 3.22 Fgl2 2.34 Ncf1 1.92 
Siglec5 3.16 Ntn1 2.32 Usp53 1.92 
Ptx3 3.15 Slamf9 2.31 Irak3 1.92 
Tlr1 3.13 Tmem176a 2.30 Slc39a14 1.92 
Arpc1b 3.07 Fcgr1a 2.29 Gpr88 1.91 
Mt1m 3.04 Jak2 2.29 Lrba 1.91 
Cxcl12 3.03 Adamts9 2.26 Sulf1 1.90 
Il1a 2.99 Usp18 2.24 Duoxa1 1.90 
Spp1 2.98 Birc3 2.24 Slc1a3 1.90 
Tmem178a 2.96 Agtr1a 2.21 Siglec8 1.90 
Lgals9 2.90 Ptpn6 2.20 LOC103693629 1.89 
Mme 2.88 Fyb 2.20 Tgfbr3 1.88 
Ccl20 2.88 Rgs16 2.19 Slc13a3 1.88 
Itgal 2.87 Cilp 2.16 Tmem176b 1.88 
Ccl4 2.85 C6 2.15 Fcgr2b 1.87 
Prkcb 2.85 C5ar1 2.14 LOC24906 1.87 
LOC500066 2.85 Cd180 2.13 Sdc4 1.86 
Fmod 2.82 Pstpip2 2.11 Msln 1.86 
Il6 2.82 Upp1 2.10 Hsd11b1 1.85 
Pik3cg 2.79 Cpxm1 2.09 Adm 1.85 
Slc11a1 2.78 Ebi3 2.09 Gsap 1.84 
Evi2b 2.78 Sema6d 2.08 Grem1 1.83 
Lifr 2.76 Serpinb2 2.08 Abcb1b 1.83 
Rasl12 2.75 Ntm 2.07 Srgn 1.83 
Pla2g7 2.69 Steap2 2.07 Nfkbia 1.82 
Itgb2 2.63 Efna5 2.06 St3gal6 1.81 
Rasgef1b 2.62 Nfkbiz 2.04 Pik3r5 1.81 
St6galnac2 2.60 Plbd1 2.04 RGD1561730 1.81 
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Ctsh 1.81 Ppap2a 1.52 Selplg 1.34 
Cxcl16 1.80 Dpep1 1.52 Plscr1 1.34 
Angptl4 1.80 Mmd 1.51 Evi2a 1.33 
Cd200 1.79 Mycbp2 1.51 Stard10 1.33 
Apoe 1.77 Lrrc25 1.50 Serpinb9 1.33 
Hs6st1 1.77 Steap1 1.50 Lpar1 1.33 
Cdon 1.77 Cdhr4 1.49 Sox4 1.33 
Il18 1.76 Bcl3 1.49 Cdc42ep5 1.33 
Enpp3 1.76 Gas1 1.48 Star 1.33 
Arhgdib 1.75 LOC681325 1.48 Mmp11 1.32 
Glul 1.75 Slfn2 1.46 Tnfrsf14 1.32 
Ncf4 1.74 Pim1 1.46 Nr1h4 1.32 
Npr3 1.74 Pla2g5 1.46 Il33 1.31 
Slco4a1 1.71 Cebpd 1.45 LOC100362819 1.31 
Fam169b 1.70 Elf5 1.45 Ank3 1.31 
Hpx 1.70 Gda 1.45 Ptk2b 1.31 
LOC681383 1.70 Spn 1.45 Aqp1 1.31 
Nrp2 1.70 NEWGENE_1565505 1.45 Ampd3 1.30 
Coro1a 1.69 Optc 1.44 Osmr 1.30 
Sh2b2 1.69 C1r 1.43 Sema5a 1.30 
Ginm1 1.68 Fbxl5 1.43 Rasgrp3 1.30 
Pik3ap1 1.68 Cacna2d3 1.43 Rasgrp1 1.29 
Angpt1 1.68 Niacr1 1.43 Tnfrsf1b 1.29 
Ccl2 1.68 Pde7b 1.42 MGC112715 1.29 
Kcnj8 1.67 Phyhipl 1.42 Tshz2 1.28 
Tpbg 1.67 Nabp1 1.42 Itgam 1.28 
Serinc2 1.66 Icam1 1.42 Fbxo32 1.28 
Chml 1.66 Mzt2b 1.41 C2 1.28 
Ltbp1 1.65 Hcls1 1.41 Fmo1 1.27 
Xdh 1.65 Pkhd1l1 1.40 Plscr2 1.26 
Slc16a2 1.65 Fcer1g 1.40 Scimp 1.26 
Gxylt2 1.64 Tfpi2 1.40 LOC678893 1.26 
Epas1 1.64 Sorcs1 1.40 Tank 1.26 
Zfand5 1.63 Gpr126 1.39 Adamts7 1.26 
Aldoc 1.63 Ddhd2 1.39 LOC102546902 1.25 
Hck 1.63 Cyth4 1.39 Prokr2 1.25 
Bmp3 1.63 Cd24 1.38 C3ar1 1.25 
Fgr 1.62 Pnrc1 1.38 Ugt1a6 1.24 
Ifitm1 1.62 Ccl6 1.38 Relt 1.24 
Ugdh 1.61 Hmox1 1.38 Klf5 1.23 
Clec4d 1.61 Sdk1 1.38 Ifitm2 1.23 
Cd274 1.61 Alox5 1.38 Fth1 1.23 
Tnfaip6 1.61 Mgst1 1.37 Ackr3 1.22 
Fxyd2 1.61 Cd4 1.37 Tagap 1.22 
St3gal1 1.59 Ptprk 1.37 Chrdl1 1.22 
Dapk1 1.59 Aif1 1.36 Bcl6 1.22 
Emilin1 1.58 LOC100360218 1.36 St5 1.21 
Bnc2 1.57 Peli1 1.36 Man1a1 1.21 
Cd72 1.57 Arhgap24 1.36 Akr1b8 1.21 
Il10 1.56 Slc11a2 1.35 Gja1 1.21 
F3 1.56 Vstm4 1.35 Cd55 1.20 
Slamf8 1.56 C7 1.35 RGD1561113 1.20 
Ednrb 1.56 Spi1 1.35 Zfp36l1 1.20 
Sh3kbp1 1.56 Col18a1 1.35 Scara5 1.19 
Slc15a3 1.55 Cybb 1.35 Tyrobp 1.19 
Il1rl1 1.54 Adora2b 1.35 Abca1 1.19 
Atp8b4 1.54 Hpgds 1.34 Rftn1 1.19 
Zc3h12a 1.54 Nckap1l 1.34 Mmp2 1.19 
Mmrn1 1.53 Bag4 1.34 Gnai1 1.18 
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Cables1 1.18 Slc5a3 1.09 Psip1 -1.01 
Tbxas1 1.18 Csf2ra 1.09 Olfml2b -1.01 
Ccl19 1.18 Cxcl13 1.09 Cxcr4 -1.01 
Fosl2 1.18 LOC103693634 1.08 Dmpk -1.01 
Rbks 1.18 Ifi47 1.08 Creb3l1 -1.01 
Nfkbie 1.18 Ebf3 1.08 Zfp64 -1.01 
Phactr2 1.17 Rcan1 1.08 Racgap1 -1.01 
Arhgap26 1.17 Laptm5 1.08 Reps2 -1.01 
Nlrp3 1.17 Egfr 1.07 Klra1 -1.02 
Tnfsf15 1.17 Oasl 1.07 Tns1 -1.02 
Fam131b 1.17 Vav1 1.07 Ecm1 -1.02 
Hgf 1.17 Fst 1.07 Itm2a -1.02 
Fbln1 1.17 Cyba 1.07 Ptpla -1.02 
Ifngr1 1.17 Nhs 1.06 Afap1 -1.02 
Galk2 1.16 Nfkb2 1.06 Pkia -1.02 
Fam213b 1.16 Prg4 1.06 Sh3pxd2a -1.02 
Cygb 1.16 Tlr7 1.06 LOC100359633 -1.03 
Slc44a1 1.16 Prr16 1.06 Mmp16 -1.03 
Lnx1 1.16 Apobec1 1.06 Gars -1.03 
Sqrdl 1.15 Gpr146 1.05 Crispld2 -1.03 
Lst1 1.15 Dgkh 1.05 Nfxl1 -1.03 
Prelp 1.15 Tmcc3 1.05 Tnfrsf10b -1.03 
P4ha3 1.15 Fgd6 1.05 Plxnc1 -1.03 
Tmem2 1.15 Naprt1 1.05 LOC103694412 -1.04 
Adamts3 1.15 P2rx4 1.05 Arhgef2 -1.04 
Il6st 1.15 C1rl 1.05 Gdf15 -1.04 
Ptgir 1.15 Rarres2 1.04 Pdlim3 -1.04 
Egln3 1.15 Rbp1 1.04 Zeb1 -1.04 
Slfn3 1.15 Tlr8 1.04 LOC100365921 -1.04 
Btg2 1.15 Hpse 1.03 Htr1f -1.04 
Ptpn1 1.14 Timp1 1.03 Plekhb1 -1.04 
Hsph1 1.14 LOC314492 1.03 Sgol1 -1.04 
Clec14a 1.14 Tifa 1.03 Plxna4a -1.05 
Itgb8 1.14 Ptgs2 1.03 Bub1 -1.05 
LOC301748 1.14 Oplah 1.02 Vcpkmt -1.05 
Ucp2 1.13 Cd53 1.02 Etv5 -1.05 
Pde4b 1.13 Wt1 1.02 Rnf144a -1.05 
Relb 1.13 Lsm1 1.02 Ldb2 -1.05 
Sbno2 1.13 Acvrl1 1.02 Ckap2l -1.05 
Pcsk5 1.13 Lcp2 1.02 Mtfr1 -1.06 
Htra4 1.12 Map4k3 1.02 Otub2 -1.06 
Plcxd3 1.12 Abcc9 1.02 Hist1h2bl -1.06 
Sept6 1.12 March3 1.01 Il1rap -1.06 
Svep1 1.12 Amigo2 1.01 Plk1 -1.06 
Art4 1.11 Crebrf 1.01 Casp12 -1.06 
Fam43a 1.11 Olfml3 1.01 Slc3a2 -1.07 
LOC102555109 1.11 Aebp1 1.00 Lmod1 -1.07 
Ksr1 1.11 Cdh2 1.00 Hist1h2ai -1.07 
Cd244 1.11 Aldh1l2 -1.00 Pde7a -1.07 
Ccl24 1.10 Ehd2 -1.00 NEWGENE_6497336 -1.07 
Scin 1.10 Cstf2 -1.00 Lmna -1.07 
Tlr6 1.10 LOC100361180 -1.00 Lama5 -1.07 
Rcl1 1.10 Pxdc1 -1.00 Hist1h2ah -1.08 
Pld5 1.10 Hspb6 -1.00 Dusp8 -1.08 
Csf1 1.10 LOC366763 -1.00 Uap1l2 -1.08 
Gramd4 1.10 Kif2c -1.00 Tfec -1.08 
Dtnb 1.09 Asb12 -1.01 Syt17 -1.08 
Tgm1 1.09 Plat -1.01 Eps15 -1.08 
Ifitm3 1.09 Mpeg1 -1.01 LOC103690838 -1.09 
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Klf2 -1.09 Slc40a1 -1.22 Kcnv2 -1.42 
Hist1h2ac -1.09 Igfbp6 -1.23 Cenpf -1.42 
Zfp385d -1.09 Epyc -1.23 Slc6a9 -1.42 
Ccnb1 -1.09 Mical2 -1.24 Hist1h2bf -1.42 
Snrpd2 -1.10 Herpud1 -1.24 Cars -1.43 
Shcbp1 -1.10 Kif23 -1.24 Ackr4 -1.43 
Pqlc3 -1.10 Tnc -1.24 Fbxl7 -1.43 
Matn2 -1.10 Pragmin -1.24 Lyrm1 -1.43 
Me1 -1.10 Lars -1.24 Sphkap -1.43 
Sdc2 -1.10 Unc5b -1.24 Slc7a3 -1.44 
Mthfd1l -1.11 Trabd2b -1.25 Shmt2 -1.44 
Mars -1.11 LOC102556004 -1.25 Nrk -1.44 
Hist1h2bcl1 -1.11 Inhba -1.25 Slc8a1 -1.45 
Mir421 -1.11 LOC691984 -1.25 Mrpl42 -1.45 
Col4a5 -1.12 Napb -1.25 LOC103690963 -1.45 
Pxdn -1.12 Xpot -1.26 Ndc80 -1.46 
Aspm -1.13 Cdh3 -1.26 Cdkl5 -1.46 
Zfp469 -1.13 Casc5 -1.26 Dbndd2 -1.47 
Lrrc17 -1.14 Ap1s3 -1.27 Mmp28 -1.47 
Pdia5 -1.14 Tmeff2 -1.27 Ncam1 -1.48 
Mybl1 -1.14 Fndc1 -1.27 Fbln2 -1.48 
Pde1a -1.14 Hmmr -1.27 Ssbp2 -1.48 
Tubb3 -1.14 St8sia2 -1.27 Ddit3 -1.48 
Oaf -1.15 Sesn3 -1.27 LOC103693330 -1.49 
Nuf2 -1.15 Psg19 -1.27 Wars -1.50 
RGD1566307 -1.15 Ttk -1.28 Capn6 -1.51 
Ncapg -1.15 Aars -1.28 Creb5 -1.51 
Kif11 -1.16 Ccdc141 -1.28 Col11a1 -1.52 
Cenpn -1.16 Itga6 -1.28 LOC102554096 -1.52 
Ccdc6 -1.16 S100a10 -1.29 Diaph3 -1.52 
Nexn -1.16 LOC100361756 -1.29 Crlf1 -1.52 
Pdgfrl -1.16 Dnajb4 -1.29 Pmepa1 -1.53 
Uchl1 -1.17 Mid2 -1.30 Pck2 -1.53 
Col3a1 -1.17 Itgb5 -1.30 Ppp1r14a -1.53 
Ccnd2 -1.17 Zmynd19 -1.31 Adamtsl2 -1.54 
Plac9 -1.17 Mki67 -1.31 Tfrc -1.55 
Col5a3 -1.17 Hist2h2ab -1.31 Sipa1l2 -1.55 
LOC100360754 -1.18 Nars -1.31 Stxbp6 -1.56 
Eprs -1.18 Hey2 -1.32 LOC100911253 -1.56 
Tubb6 -1.19 Top2a -1.32 Ppp1r14c -1.57 
Ncaph -1.19 Ect2 -1.32 Mmp12 -1.58 
C1qc -1.19 Pcdh18 -1.32 Prune2 -1.59 
Gata3 -1.19 Cenpe -1.33 Psph -1.61 
Ccna2 -1.20 Gpr34 -1.33 Pdlim7 -1.61 
Arhgap6 -1.20 Bcat1 -1.33 Sdpr -1.61 
Plau -1.20 Peg10 -1.34 Esco2 -1.62 
Fam107b -1.20 Sesn2 -1.35 Dmd -1.62 
Slc1a4 -1.21 Gpr64 -1.35 Cd74 -1.64 
Ifi27l2b -1.21 Olr1 -1.36 Dysf -1.65 
Cap2 -1.21 Tsc22d3 -1.36 LOC103690836 -1.66 
Adam19 -1.21 Igfbp5 -1.37 Nrep -1.68 
Atp2b4 -1.21 Rgs17 -1.38 Rgs4 -1.70 
Kif2a -1.22 Pycr1 -1.39 Aldh1a1 -1.70 
Hadhb -1.22 Depdc1 -1.40 Tubb2a -1.72 
Prrg4 -1.22 Jam2 -1.40 Notch3 -1.73 
Sema3d -1.22 Cth -1.41 Aoc3 -1.74 
LOC499229 -1.22 Bambi -1.41 Casp4 -1.75 
Daam1 -1.22 Anln -1.41 Jun -1.75 
Rhob -1.22 LOC103692529 -1.41 Mrgprf -1.76 
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Gucy1b3 -1.76 
Slc7a1 -1.77 
Enpp1 -1.78 
Zdhhc2 -1.78 
Itgb3 -1.78 
Timp3 -1.80 
RT1-Da -1.81 
Prss35 -1.81 
Cntnap2 -1.81 
Adarb1 -1.82 
Cthrc1 -1.84 
Olr63 -1.85 
LOC103690839 -1.86 
Plxdc2 -1.87 
Mthfd2 -1.88 
Asns -1.88 
Loxl2 -1.89 
Cnn1 -1.95 
Cx3cr1 -1.95 
Galnt18 -1.96 
Fras1 -1.98 
Chac1 -1.99 
Fam129a -2.01 
LOC102546963 -2.02 
Slc7a5 -2.03 
Atf5 -2.09 
Ms4a4a -2.10 
LOC103690837 -2.12 
Psat1 -2.15 
Sox9 -2.17 
Itga11 -2.18 
Itga4 -2.18 
Tgfb3 -2.28 
Col6a3 -2.40 
Cmklr1 -2.42 
Piezo2 -2.45 
Serpine2 -2.50 
Trib3 -2.57 
C1qb -2.64 
Mcam -2.74 
Gucy1a3 -3.00 
Eln -4.08 
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